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Overview  
Part 1 of this thesis is a qualitative narrative systematic literature review which 
examines how the administration of acute sub-anaesthetic ketamine affects cognitive 
function in non-healthy patients in medical and psychiatric settings. Ten studies were 
included in the review, and study quality, the effect of ketamine on cognition, and 
ketamine’s effect on the medical and psychiatric problems identified is discussed.  
Part 2 describes a study of chronic pain patients receiving either acute sub-
anaesthetic intravenous ketamine or lidocaine. It measures participant pain and 
cognitive performance before and after drug administration, and explores the 
relationships between pain, cognition and the drugs administered. This was a joint 
project carried out by two UCL Doctorate in Clinical Psychology trainees. The partner 
project evaluates the effect of ketamine on mood. All work was completed jointly by the 
two researchers. 
Finally, Part 3 of this thesis, the Critical Appraisal, discusses the process of 
completing this piece of research. 
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Impact Statement 
This thesis consisted of two major parts: a systematic literature review 
examining how the administration of acute sub-anaesthetic ketamine affects cognitive 
function in non-healthy patients in medical and psychiatric settings, and a non-
randomised between-subjects study of the effects of sub-anaesthetic IV infusions of 
ketamine compared to the effects of IV infusions of lidocaine on the cognitive 
functioning in participants receiving the drugs for chronic pain. 
The literature review indicated that while ketamine appears to provide useful 
relief for persons suffering with treatment resistant depression, and may provide some 
relief in post-surgical patients, there is not enough research on the cognitive effects of 
acute non-anaesthetic ketamine. Literature on the chronic and recreational use of 
ketamine is prevalent, but it is important that further study be carried out on the 
cognitive ramifications of acute sub-anaesthetic ketamine administered to medical and 
psychiatric patients.   
Though chronic neuropathic pain is a costly burden at the individual, social and 
economic levels, and can lead to absenteeism, reduced productivity and long-term 
incapacity, there is still no readily available pharmacological treatment that works for 
all patients. Indeed, though research on the pain relieving properties of NMDA receptor 
antagonists has been ongoing for almost three decades, little is known about the 
cognitive effects of acute sub-anaesthetic doses of ketamine in patients with chronic 
neuropathic pain.  
The findings of this study indicated that acute ketamine worked to significantly 
reduce pain, and indeed provided significantly more short-term more pain relief than 
lidocaine. Due to this, further research should focus on the longer term pain relieving 
properties of the drug, and on comparisons of ketamine’s efficacy to other common 
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analgesics, so that medical personnel can be more confident in the use of ketamine for 
the relief of chronic pain. 
However, as ketamine impaired working memory, and as episodic memory for 
information learned under the influence of the drug was also impaired by ketamine 
administration, further research on the cognitive consequences of long term and 
repeated ketamine administration in persons with chronic pain is needed. 
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1.1 Abstract  
Aims: This qualitative narrative systematic literature review aimed to examine how the 
administration of acute sub-anaesthetic ketamine affects cognitive function in non-
healthy patients in medical and psychiatric settings.  
Methods: Database searching in EMBASE, PsycINFO and MEDLINE followed by 
application of inclusion criteria identified 10 studies which were analysed and used in 
this review. Study quality was assessed using an amended version of the Checklist for 
Measuring Study Quality in Randomised Controlled Trials and Non-randomised Trials 
by Downs and Black (1998). 
Results: Six studies looked at ketamine use in psychiatric settings, while four took 
place in a medical setting. Studies were described and overall quality of the studies was 
assessed in terms of their quality of reporting and external and internal validity. The 
effect of ketamine on the cognitive functioning of participants was reported, and finally 
the effect of ketamine on the various medical and psychiatric problems was reported. 
Conclusions: Studies reviewed differed in their overall quality and their reported 
effects of ketamine on cognition, as well as the effects of ketamine on medical and 
psychiatric problems. These differences are discussed, as are limitations of the current 
review. 
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1.2 Introduction 
Ketamine is a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) 
receptor, developed as a replacement human anaesthetic for phencyclidine (PCP). 
Because it does not impair spontaneous respiration or block the airways and works to 
produce both amnesia and analgesia when used for anaesthetic purposes, it has been a 
part of the World Health Organisation’s (WHO) Essential Medicines List since 1985 
(WHO, 2016). As this is the method in which it is most bioavailable, ketamine is most 
often administered intravenously, however it can be administered by intramuscular, 
intrarectal, intranasal or oral routes (Mion &Villevielle, 2013). The WHO Expert 
Committee on Drug Dependence indicates that though ketamine is used recreationally 
worldwide and chronic recreational use can cause adverse side effects, the medical 
usefulness of the drug is such that it should not be controlled under international drug 
control conventions (WHO, 2016).  
1.21 The Use of Ketamine in Medical & Psychiatric Settings 
Along with its use as an anaesthetic, ketamine has been employed to treat a range 
of medical and psychiatric problems. Ketamine appears to be effective in treating both 
chronic and acute pain.  Anaesthetic dosages of ketamine resulted in significant levels 
of pain reduction and increased physical functioning in complex regional pain syndrome 
(CRPS) patients for periods of up to 6 months (Keifer et al, 2008). Additionally, sub-
anaesthetic doses of IV ketamine appear to provide short term relief of chronic 
neuropathic pain, to reduce the need for opioid analgesics, and to effectively control 
post-operative pain (Bell, 2009; Nourouzi et al, 2010; Subramaniam, Subramaniam & 
Steinbrook, 2004; Visser & Schug, 2006). Ketamine has also been used for the 
treatment of opioid-tolerant cancer pain, with mixed results (Bell, Eccleston & Kalso, 
2017). 
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Research indicates that drugs which modulate the NMDA receptor may aid in 
treating depression (Matthews, Henter & Zarate, 2012). Several research trials have 
found that sub-anaesthetic doses of ketamine produce a time limited antidepressant 
effect in patients with refractory or treatment resistant major depression, and in patients 
with refractory or treatment resistant bipolar depression (Abdallah, Averill & Krystal, 
2015; Berman et al, 2000; Fond et al, 2014; Lara, Bisol & Munari, 2013). A review by 
Abdallah et al (2015), also suggests that ketamine may be useful in treating trauma-
related disorders, and recent research indicates that sub-anaesthetic doses of intravenous 
ketamine may be effective in ameliorating the symptoms of post-traumatic stress 
disorder (Albott et al, 2017). 
Interestingly, ketamine may be a more effective treatment for depression in 
patients with a family history of alcoholism (Luckenbaugh et al, 2012), and indeed, 
research from as long as two decades ago indicates that there may be a reduction in 
relapse rates in alcoholics who receive a combination of ketamine and “psychotherapy” 
(Krupitsky & Grinenko, 1997). There may also be an effect of ketamine on relapse rates 
and intensity of cravings in recovering heroin addicts (Krupitsky et al, 2002). 
1.22 Cognition 
Cognition can be broadly defined as the way in which the brain acquires, 
processes, stores and retrieves information (Lawlor, 2002). Cognitive functions include 
psychomotor speed, the executive functions (such as attention, inhibition, planning, 
switching, searching, use of strategy and flexible thinking) and the various types of 
memory: episodic memory, semantic memory, working memory, procedural memory 
and the perceptual representation system (Kalechstein, De La Garza, Mahoney, 
Fantegrossi & Newton, 2007; Tulving & Donaldson, 1972; Rasmussen, 2005; Schacter, 
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1990). It is important to note that the cognitive domains discussed are not rigidly 
separate categories, and there is no neurocognitive task that can test only one domain. 
1.23 Ketamine & Cognition: Healthy Participants 
Ketamine research has largely focused on the cognitive effects of recreational 
ketamine, or on the cognitive effects of ketamine as a general anaesthetic. Frequent, 
long-term recreational ketamine users appear to experience cognitive disruptions, 
especially related to their episodic and semantic memory, but also related to spatial 
working memory and visual recognition (Morgan & Curran, 2006; Morgan, 
Muetzelfeldt & Curran, 2010; Morgan & Curran, 2011; Visser & Schug, 2006). Persons 
who experience these impairments in cognition may not see a return to pre-drug 
functioning (Morgan & Curran, 2006). When used as a general anaesthetic, ketamine 
does not appear to impair cognitive function, and may indeed attenuate post-operative 
cognitive dysfunction (Deiner & Silverstein, 2009; Hudetz et al, 2009; Koffler et al, 
2016; Lee et al, 2015). However, there is less research exploring the effect of acute sub-
anaesthetic ketamine on cognitive functioning.  
Healthy participants administered low and high doses of acute sub-anaesthetic 
intravenous ketamine (target plasma levels of 50ng/ml and 100ng/ml) or placebo 
(saline) found disruptions in the manipulation of information in working memory, but 
no significant differences in visual perception, spatial working memory, or the ability to 
carry out a planning task (Honey et al, 2003). Acute sub-anaesthetic ketamine 
administered to healthy volunteers had little effect on the results of verbal fluency tasks 
as compared to a placebo (Fu el at, 2005). However, the latter study reported 
neuroimaging evidence indicating that for more demanding tasks, ketamine-
administered participants had increased activity in the anterior cingulate, prefrontal, and 
striatal regions (Fu et al, 2005). 
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In healthy volunteers, a dose of acute sub-anaesthetic IV ketamine (0.4 or 0.8 
mg/kg) as compared to a saline placebo appears to impair response inhibition (Morgan, 
Mofeez, Brandner, Bromley & Curran, 2004b). This study found that acute ketamine 
impaired episodic memory for information learnt under the influence of the drug but did 
not impair information learnt before ketamine was administered and did impair 
semantic memory. Further research has also indicated that an acute dose (0.4 or 0.8 
mg/kg) of ketamine produces a dose-dependent impairment in episodic and working 
memory in healthy participants (Morgan, Mofeez, Brandner, Bromley & Curran, 
2004a). Ketamine also acted to slow semantic processing and impair recognition 
memory and procedural learning (Morgan et al, 2004a).  
A review of the cognitive effects of acute ketamine found that the processing of 
semantic memory may be impaired (Morgan & Curran, 2006). Episodic memory 
appears to be impaired for information learned on ketamine, but not for the recall of 
information learned before drug administration (Morgan & Curran, 2006). As this 
review also indicated that ketamine may impair the encoding aspect of procedural 
learning, it can be suggested that ketamine may impair the encoding of information into 
memory (Morgan & Curran, 2006). The authors of this 2006 review found that while it 
was unclear if sustained attention was impaired by ketamine, tasks assessing simple 
attention and selective attention appeared largely unimpaired by the drug. Additionally, 
ketamine appeared to have little impact on other tasks of executive function once 
deficits in memory were controlled for (Morgan & Curran, 2006). Finally, the 
maintenance of information in working memory appears to be unaffected by ketamine 
administration, however impairments are seen in the manipulation of information in 
working memory (Morgan & Curran, 2006). 
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 More recent research appears to agree with findings from Morgan and Curran’s 
2006 review. A study of healthy participants receiving a dose of sub-anaesthetic 
ketamine or placebo found that as the difficulty of a visual working memory task 
increased, the performance of participants administered ketamine decreased 
significantly compared to those receiving placebo (Koychev, Deakin, El-Deredy, & 
Haenschel, 2017). Healthy participants who experienced induced heat pain and were 
then administered an acute dose of ketamine, demonstrated significantly impaired 
cognition in the domains of memory, psychomotor speed, complex attention, and the 
executive function of cognitive flexibility as compared to their placebo counterparts 
(Olofsen et al, 2012). There was a smaller, but still significant, impairing effect of 
ketamine on reaction time (Olofsen et al, 2012). Finally, a study of healthy participants 
administered three increasing doses of ketamine found that ketamine produced dose 
dependant effects on tasks of complex reaction time, visuospatial working memory and 
spatial planning, but no effect on simple reaction time (Hayley et al, 2017). This study 
also reported a post-drug return to baseline performance in all domains (Hayley et al, 
2017). 
1.24 Ketamine & Cognition: Medical and Psychiatric Patients 
There is less research on the cognitive effects of acute ketamine for medical or 
psychiatric problems. A study of complex regional pain syndrome patients found that 
participants who had long-term frequent ketamine infusions (at least twice a month for 
six months) performed significantly worse on measures of attention, working memory, 
semantic memory, and psychomotor coordination than those who never or infrequently 
received ketamine (Kim, Cho & Lee, 2016).  
A review of sub-anaesthetic ketamine for suicidality in treatment resistant 
depression (TRD) indicated that acute administration of the drug may lead to 
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improvements in visual memory, simple working memory, and complex working 
memory (Lee et al, 2016). It is important to note however, that these cognitive changes 
are reported alongside a simultaneous reduction in depression. Persons with depression 
often experience impaired cognition, especially in the domains of attention, reaction 
time and memory (Gotlib & Joormann, 2010), and it is possible that a decrease in 
depression may have led to an increase in cognitive functioning. This review also 
indicated that participants with low pre-ketamine attention and processing speed may be 
more likely to see a mood response to ketamine (Lee et al, 2016). 
1.25 Aims of the Current Review 
The acute effects of ketamine outlined stem largely from research on healthy 
participants in a laboratory setting. Indeed, a 2015 review of ketamine for depression in 
bipolar disorder found no double-blind, randomised, placebo-controlled trials in patient 
groups which assessed cognitive function (McCloud et al, 2015). There is therefore a 
need for a comprehensive review of the acute effects of ketamine in non-healthy 
participants. This systematic literature review aims to examine how the medical and 
psychiatric use of acute sub-anaesthetic ketamine affects cognitive function in studies 
with more robust external validity. That is, in studies which recruit participants 
representative of the population the intervention is aimed at – patients, not healthy 
controls. It also aims to explore other reported effects of acute sub-anaesthetic ketamine 
used in various medical and psychiatric disorders. 
1.3 Method 
1.31 Search Strategy 
As literature related to ketamine and neuropsychological functioning can be found 
in medical, psychological and psychiatric resources, a systematic literature search was 
carried out using three electronic databases: EMBASE, MEDLINE, and PsycINFO. 
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The thesaurus function on the EMBASE and PsycINFO databases, and the “tree” 
function on the MEDLINE database were used to find broader terms and words related 
to the search terms memory, brain function, cognition, mental function and 
neuropsychology. The search terms were collated, and duplicates and unsuitable terms 
were removed (See: Appendix 1.A: Creation of Search Terms). This search process was 
designed to be wide and inclusive, so that relevant studies would not be lost.  
In each of the databases explored, searches of terms related to neuropsychological 
functioning were combined with the results of a search for ketamine using the Boolean 
operators “AND” or “OR”. These searches were then limited to studies that were 
written in English, that used human adult participants, and to those that used a clinical 
trial methodology (See: Appendix 1.B: Search Process).  
After duplicates were removed, the abstracts of these studies were screened 
according to inclusion criteria. Initially, each study was required to contain a control 
group, and each group needed to include at least 12 participants. However, this resulted 
in only five eligible studies. As a result of this, studies were screened to meet the 
following criteria: 
1. Ketamine was used with a medical or psychiatric population 
2. Ketamine was administered at sub-anaesthetic doses 
3. Objective neuropsychological tasks were used to measure cognitive function 
4. Studies were published in an English language peer-reviewed journal 
Studies that appeared to meet these criteria were selected for further, full text 
review to ensure relevance (See: Figure 1.1: Selection of Included Studies). This full 
search process retrieved all articles that met inclusion criteria for this review. Data from 
these articles, including author and source information, study design, medical or 
psychiatric context of the study, domains of cognition assessed, and dosages of 
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ketamine and active control or placebo used, was extracted to create a table of article 
characteristics (See Table 1.1: Characteristics of Included Studies).  
This literature review uses a qualitative narrative approach, as the studies 
identified differ widely in their administrative route of ketamine, the doses of ketamine 
used, the medical and psychiatric problems they address, and the control or active 
control drugs that they use. Because of this, a quantitative analysis of this small number 
of studies would not be meaningful.  
1.32 Assessment of Study Quality 
Study quality was assessed using an amended version of the Checklist for 
Measuring Study Quality in Randomised Controlled Trials and Non-randomised Trials 
by Downs and Black (1998) (See Appendix 1.C: Tool Used to Assess Study Quality). 
This is a 26-item scale that assesses studies by the overall study quality as well as 
external validity, and internal validity – bias and confounding. This tool was used as it 
is one of the few measures for assessing study quality that can be applied to controlled, 
non-controlled, randomised and non-randomised studies. It has been tested and meets 
acceptable criteria for face, content and criterion validity. It also meets acceptable 
standards for internal consistency, test-retest reliability, and inter-rater reliability 
(Downs & Black, 1998).  
1.4 Results 
As outlined in Figure 1.1, database searching in EMBASE, PsycINFO and 
MEDLINE identified 4,468 relevant items. Refining the search to include only clinical 
trials in English, with adult human participants identified 283 items, 219 with duplicates 
removed. 197 studies were excluded after title and abstract screening if they examined 
ketamine as a general anaesthetic, used healthy participants, did not use ketamine or 
assess cognitive function, or used paediatric or non-human participants. 
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A further four potentially relevant studies were retrieved from a hand search of 
reference lists, giving a total of 26 studies retrieved in full for detailed analysis. 16 of 
these studies were excluded as they did not measure cognition or utilised subjective 
measures of cognition, used healthy participants, did not use a trial methodology or 
were reported as conference abstracts. The 10 studies which remained were analysed 
and used in this review. 
Figure 1.1 
Selection of Included Studies 
 
219 studies identified from literature search 
 
  
 
 
  
 
197 Studies excluded after screening of title and abstract due to 
- Ketamine for general anaesthesia (n=38) 
- Healthy participants (n=99) 
- Did not use ketamine (n=16) 
- Cognition not assessed (n=26) 
- Paediatric participants (n=5) 
- Non-human sample (n=1) 
- Other (n=8) 
 
  
   
   
4 potentially relevant 
studies retrieved from other 
sources (i.e., hand search) 
 
 
 
 
  
 
26 studies retrieved in full for detailed analysis 
 
  
 
 
  
 
16 studies excluded  
 
  
 
 
  
 
10 studies included in review 
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1.41 Description of Studies 
10 studies meeting the amended inclusion criteria and published between January 
1996 and March 2018 were identified. The studies were undertaken in various countries 
– six in the USA, two in Australia, one in Israel and one in France. (See Table 1.1: 
Characteristics of Included Studies).  
Methodology. Six studies used an active control and had a randomised, double-
blinded, between-subjects methodology (Reeves, Lindholm, Myles, Fletcher & Hunt, 
2001; Zohar et al, 2002; Aubrun et al, 2008; Murrough et al, 2015; Grunebaum et al, 
2017; Gálvez et al, 2018). Three studies were placebo controlled quasi-randomised and 
double-blinded, and of these, two used a within-subjects design (Malhotra et al, 1997; 
Murman et al, 1997), and one used a between-subjects design (LaPorte, Lahti, Koffel, & 
Tamminga, 1996). One study used a within-subjects open label design and had no 
control or blinding (Shiroma et al, 2014). 
Study Context. Of the 10 studies included, four examined ketamine’s effect on 
cognitive function in a medical context, and six in a psychiatric context. One study used 
medical ketamine in participants with Huntington’s disease (Murman et al, 1997), while 
three used ketamine for the relief of acute post-surgical pain (Reeves et al, 2001; Zohar 
et al, 2002; Aubrun et al, 2008).  In studies of psychiatric conditions, ketamine was used 
in participants with treatment resistant depression (TRD) in three studies (Shiroma et al, 
2014; Murrough et al, 2015; Galvez et al, 2018), and participants with bipolar 
depression in one study (Grunebaum et al, 2017). Participants in two studies were 
diagnosed with schizophrenia (LaPorte et al, 1996; Malhotra et al, 1997). These studies 
did not use ketamine as treatment, but instead were exploring the ways in which 
ketamine affects people with a diagnosis of schizophrenia. 
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Table 1.1 
Characteristics of Included Studies 
1a. Participants with a medical diagnosis 
Author/ Year/  
Country/ Source 
 
Study Design Context Ketamine Comparator Patient 
Characteristics 
Cognitive Assessment Results 
1997 
Murman et al 
USA 
Neurology, 49, 
153-161 
 
Placebo 
controlled 
 
Quasi-
randomised (to 
placebo/ 
ketamine on 
first day)  
 
Double blinded 
 
Within-subjects 
Medical: 
Huntington’s 
Disease 
IV ketamine 
 
Escalating doses: 
0.10, 0.40 & 0.60 
mg/kg/hr 
IV placebo Huntington’s 
Disease & Mild 
Cognitive 
Impairment 
 
N=10 
4 male/ 6 female 
Age (yrs) = ranged 
from 28-67 
(average=48.4)  
 
 
Cognitive Testing 
Procedure: 
All repeated 20 min 
post dose change 
 
Domains tested: 
Verbal memory – 
immediate & delayed 
Visual memory – 
immediate & delayed 
Verbal fluency 
Attention (reaction 
time and digit span) 
Psychomotor agility 
 
At the 0.4 dose of 
ketamine immediate 
verbal memory, delayed 
visual memory & verbal 
fluency was impaired 
 
At the 0.6 dose 
immediate visual 
memory, psychomotor 
agility and one measure 
of attention (reaction 
time) was impaired 
 
Delayed verbal memory 
and attention (digit span) 
was not affected by 
ketamine in any dose 
 
2001 
Reeves et al 
Australia 
Anesthesia & 
Analgesia 
93(1), 116–20  
 
Active control 
 
Randomised 
 
Double-Blinded  
 
Between-
subjects 
Medical: 
Pain 
IV ketamine & 
morphine 
(patient 
controlled) 
 
ketamine 1 
mg/ml + 
IV morphine 
(patient 
controlled) 
 
morphine 1 
mg/mL 
Post abdominal 
surgery  
N=71 
 
Morphine & 
Ketamine: 
N=36 
Cognitive Testing 
Procedure: 
Baseline (pre-op) & at 
48h post-op  
 
Domains tested 
Psychomotor agility with 
switching significantly 
impaired in morphine & 
ketamine group 
(P=0.037) 
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morphine 1 
mg/ml 
20 male/ 16 
female 
Age (yrs) = 54± 13 
 
Morphine only:  
N=35 
16 male/ 19 
female 
Age (yrs) = 47 ± 
14 
 
Attention/ 
psychomotor agility 
(trails A) 
 
Switching/ 
psychomotor agility 
(Trails B)  
 
2002 
Zohar et al 
Israel 
Journal of Clinical 
Anaesthesia 14(7), 
505–511, 2002 
 
 
Active control 
 
Randomised 
 
Double blinded 
 
Between-
subjects 
Medical: 
Pain 
Wound 
infiltration of 
bupivacaine & 
ketamine (patient 
controlled) 
 
0.125% 
bupivacaine & 
ketamine (1 
mg/mL) 
Ceiling of 
9ml/hour 
 
Rescue morphine 
if needed 
 
Wound 
infiltration of 
bupivacaine 
(patient 
controlled) 
 
0.125% 
bupivacaine 
Ceiling of 
9ml/hour 
 
Rescue 
morphine if 
needed 
Post C-Section 
N=50 
All female 
 
Bupivacaine & 
ketamine: 
N=25 
Age (yrs) =33 ± 6 
(20-45) 
 
Bupivacaine 
alone: 
N=25 
Age (yrs) = 32 ± 6 
(21-43) 
Cognitive Testing 
Procedure: 
Baseline (pre-op), 
immediately post-op, at 
2 hour-intervals while 
in recovery & at 24h 
post-op  
 
Domains tested: 
Digit Substitution Test 
& Mini-mental test 
[find further info on 
test domains] 
No s.d.in cognitive 
functioning 
 
No s.d. in: 
Analgesia 
Use of drug 
Morphine consumed 
Pain satisfaction 
2008 
Aubrun et al 
France 
European Journal 
of Anaesthesiology, 
25(2), 97–105 
 
Active control 
 
Randomised 
 
Double blind 
 
Between-
subjects 
 
Medical: 
Pain 
IV ketamine & 
morphine 
(patient 
controlled) 
 
Morphine 
1mg/mg & 
ketamine 
0.5mg/ml 
IV morphine 
(patient 
controlled) 
 
Morphine 
1mg/ml 
 
Patients having 
abdominal 
gynaecological 
surgery 
N=90 
All female 
 
Ketamine: 
N=45 
Cognitive Testing 
Procedure: 
Baseline (pre-op); 
Immediately post-op; 
Day 1 - a.m.; Day 2 - 
a.m.; Day 2 - p.m. 
 
Domains tested: 
Orientation 
No s.d. in cognitive 
functioning between 
ketamine and placebo 
 
No s.d. between pre- & 
post-op cognitive 
functioning 
 
No s.d. in: 
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Age (yrs) =50 ± 10 
 
Morphine: 
N=45 
Age (yrs) =49 ± 12 
 
Registration 
Recall 
Attention 
Verbal fluency 
Memory (and 
processing speed? 
DSST/Coding) 
Working memory 
Pain relief 
Additional morphine 
Adverse effects 
Mood 
 
1b. Participants with a psychiatric diagnosis 
Author/ Year/  
Country/ Source 
 
Study Design Context Ketamine Comparator(s) Patient 
Characteristics 
Cognitive 
Assessment 
Results 
1996 
LaPorte et al 
USA 
Journal of 
Psychiatric 
Research, 30(5), 
321-330 
 
Placebo controlled 
 
Quasi-randomised 
[treatment 
counterbalanced] 
 
Double blinded 
 
Between-subjects 
Psychiatric: 
Schizophrenia 
Injection of 
ketamine 
 
0.5 mg/kg 
Injection of placebo Right-handed 
people with a 
diagnosis of 
schizophrenia  
 
N=7 
5 male/ 2 
female 
Age (yrs) = 
27.3; ranged 
from 22-36 
 
 
 
Cognitive Testing 
Procedure: 
Pre-injection and 
30-45min post-
injection 
 
Domains Tested 
Control tasks used 
to rule-out 
generalized 
impairment: 
Verbal fluency 
Visuospatial 
 
Pre & Post drug: 
Learning 
Immediate & 
delayed verbal 
memory 
Visual memory  
No significant drug vs 
placebo differences in 
cognition 
 
Learning score lower 
following ketamine 
administration (non-
significant) 
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1997 
Malhotra et al  
USA 
Neuropsycho-
pharmacology, 
17(3), 141-150 
Placebo controlled 
 
Within-subjects & 
between- subjects 
(people with a 
diagnosis of 
schizophrenia & 
healthy 
participants)  
 
Double blinded 
 
 
 
Psychiatric: 
Schizophrenia 
IV ketamine 
 
Bolus of 0.12 
mg/kg of 
ketamine 
followed by 
1hr infusion of 
0.65 mg/kg of 
ketamine 
 (total dose of 
0.77 mg/kg/hr) 
IV placebo 
 
Saline infusion of 1 
hour 
Diagnosis of 
Schizophrenia: 
N=13 
10 male/ 3 
female 
Age (yrs) = 
31.3 ± 2.8 
 
Healthy: 
N=16 
12 males/ 4 
females 
Age (yrs) = 
27.8 ± 1.9 
 
Cognitive Testing 
Procedure: 
Baseline at 30min 
pre-infusion 
Testing at 10min, 
55min, 90min and 
120min post-
infusion 
 
Domains tested: 
Attention  
Verbal memory- 
recall 
Verbal memory- 
recognition 
 
Ketamine impaired 
recall & recognition 
memory in healthy 
participants and those 
with a diagnosis of 
schizophrenia. 
 
Participants with a 
diagnosis of 
schizophrenia were 
significantly more 
impaired in recall than 
healthy participants 
 
Attention was not 
significantly impaired by 
ketamine in either group. 
 
2014 
Shiroma et al 
USA 
International 
Journal of 
Neuropsycho-
pharmacology, 
17(11), 1805–
1813 
 
 
Open label study 
 
No control 
 
No blinding 
 
Within-subjects 
Psychiatric: 
treatment 
resistant 
depression 
IV ketamine 
 
0.5 mg/kg 
ketamine HCl 
over 40 min 
per session 
 
6 sessions in 
two weeks 
(Mon; Wed; 
Fri; Mon; Wed 
Fri) 
 
 
 
N/A TRD 
participants 
 
N=15 (28-69) 
All male 
Age (yrs) = 
mean 52; no 
range given 
Cognitive Testing 
Procedure: 
Pre-infusion 
baseline and after 
completion of all 6 
infusions at each 
follow-up (week 3, 
4, 5 & 6) 
 
Domains tested: 
Attention 
Working memory – 
simple & complex 
Visual memory 
Verbal memory 
Processing speed 
Set shifting 
(switching) 
Significant improvement 
in simple & complex 
working memory and 
visual memory. These 
changes are n.s. when 
change in depression 
accounted for. 
 
No s.d. in other 
cognitive domains 
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2015 
Murrough et al 
USA 
Neuropsycho-
pharmacology, 
40(5), 1084–1090 
 
 
 
 
 
 
 
 
 
Active control 
 
Randomised (2 
ketamine: 1 
midazolam) 
 
Double-blind 
 
Between-subjects 
Psychiatric: 
Treatment 
resistant 
depression 
IV ketamine  
 
Ketamine 0.50 
mg/kg over 40 
min 
IV midazolam 
 
Midazolam 0.045 
mg/kg over 40 min 
Total N=62 
28male/ 34 
female 
Age (yrs) = 
46.1 ± 12.2 
 
Ketamine: 
N=43 
Age (yrs) =47.1 
± 12.6 
19 male/ 24 
female 
 
Midazolam: 
N=19 
Age (yrs) =43.8 
±11.0 
9 male/ 10 
female 
 
Cognitive Testing 
Procedure: 
Within 1 week pre-
infusion & 
7 days post infusion 
 
Domains tested: 
Category fluency 
Processing speed 
Working memory 
Verbal learning 
Visual learning 
Reasoning/ problem 
solving  
 
Significant improvement 
in processing speed and 
verbal & visual learning 
in ketamine and 
midazolam groups 
(when controlling for 
change in depression) 
 
No sig. effect of 
ketamine on cognition 
 
No sig. effect of anti- 
depressant response on 
cognition  
2017 
Grunebaum et al 
USA 
Bipolar Disorders, 
19(3), 176–183. 
 
 
Active control 
 
Randomised 
 
Double blind 
 
Between-subjects 
 
 
Psychiatric: 
bipolar 
depression 
IV ketamine 
 
racemic 
ketamine HCl 
0.5 mg/kg 
100 mL of 
normal saline 
over 40 
minutes 
IV midazolam 
 
midazolam 0.02 
mg/kg in 
100 mL of normal 
saline over 40 
minutes 
Ketamine: 
N=7 
Age (yrs)= 39 ± 
10.2 
4 male/ 3 
female 
 
Midazolam:  
N=9 
Age (yrs) = 43 
± 13.9 
2 male/ 7 
female 
 
 
Cognitive Testing 
Procedure:  
At baseline &  
Participants 
performed a 
neurocognitive 
battery at baseline 
and day 1 testing  
 
Domains tested: 
Reaction time 
Processing speed 
Attention 
Memory 
Working memory 
Improved reaction time, 
attention and memory in 
both groups 
 
Verbal fluency declined 
in ketamine vs 
midazolam groups 
 
NB: correlations of 
cognition to 
improvements in 
depression severity 
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Pattern separation 
Verbal fluency 
Impulsiveness 
 
2018 
Gálvez et al 
Australia 
Journal of 
Psychopharma-
cology, 32(4), 
397–407 
 
 
Active control 
 
Randomised 
 
Double blind 
 
Between-subjects 
 
Psychiatric: 
Treatment 
resistant 
depression 
Intranasal 
ketamine  
 
ten sprays of 
100 mg of 
ketamine 
(ketamine HCl 
200 mg/2 mL, 
Ketalar®) 
3/week for 2 
weeks, then 
weekly for 2 
weeks 
 
Intranasal 
midazolam 
 
ten sprays of 4.5 mg 
midazolam 
(midazolam HCl, 
Hypnovel® 5 
mg/mL, diluted with 
0.9% saline) 
3/week for 2 weeks, 
then weekly for 2 
weeks 
Ketamine: 
N=3 
1 male/ 2 
female 
Age (yrs) = 
ranged from 52-
64 
 
Midazolam: 
N=2 
2 male 
Age (yrs) = 
ranged from 41-
59 
Cognitive Testing 
Procedure:  
Baseline & 48–72 
hr after treatment 
course 
 
Domains tested: 
Verbal memory 
Visual memory 
Working memory 
Set-shifting 
Reaction time  
1 ketamine participant 
sig. impaired in reaction 
time 
 
1 midazolam participant 
sig. impaired in working 
memory 
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Sample sizes.  The total number of participants included in this review was 371. 
The smallest sample size was 5 (Galvez et al, 2018) and the largest was 90 (Aubrun et 
al, 2008). 
Treatment. Doses of ketamine ranged from 0.10mg/kg (Murman et al, 1997) to 
0.77mg/kg (Malhotra et al, 1997). The time-period of treatment and number of 
treatments also varied. Seven studies gave one acute dose of ketamine (LaPorte et al, 
1996; Malhotra et al, 1997; Reeves et al, 2001; Zohar et al, 2002; Aubrun et al, 2008; 
Murrough et al, 2015; Grunebaum et al, 2017), one administered serial escalating doses 
during the testing day (Murman et al, 1997), one administered six doses of ketamine 
over two weeks (Shiroma et al, 2014) and one administered eight doses over four weeks 
(Galvez et al, 2018). 
Ketamine was administered by various routes. Seven studies administered 
ketamine via intravenous infusion (Malhotra et al, 1997; Murman et al, 1997; Reeves et 
al, 2001; Aubrun et al, 2008; Shiroma et al, 2014; Murrough et al, 2015; Grunebaum et 
al, 2017), one study used a subcutaneous injection (1996, LaPorte), and one study 
utilised an intranasal spray (Galvez et al, 2018). Finally, Zohar et al (2002) utilised 
wound infiltration of the surgical site to deliver treatment, a process by which analgesia 
is delivered directly to the wound via a catheter embedded in the skin. 
Of the six studies which used an active control, three used midazolam (Murrough 
et al, 2015; Grunebaum et al, 2017; Galvez et al, 2018), two used morphine (Reeves et 
al, 2001; Aubrun et al, 2008), and one used bupivacaine (Zohar et al, 2002). Route of 
administration of placebo or active control was the same as ketamine in all studies. 
Cognition. All studies assessed pre-treatment cognitive function. Four studies re-
assessed cognition between 20 and 120 minutes post-administration (LaPorte et al, 
1996; Murman et al, 1997; Malhotra et al, 1997; Grunebaum et al, 2017). Of the 
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remaining six studies, two re-assessed cognitive function both post- treatment and at 24 
hours post treatment (Zohar et al, 2002; Aubrun et al, 2008). Two assessed cognition 
between 48 and 72 minutes post treatment (Reeves et al, 2001; Galvez et al, 2018), one 
study had a seven-day cognitive follow up (Murrough et al, 2015), and the final study 
assessed cognitive functioning post-treatment weekly for four weeks (Shiroma et al, 
2014). 
Domains of cognition varied, as did neuropsychological tests used. Participant 
memory was assessed in eight of the 10 studies, attention in six, psychomotor agility in 
four, and processing speed in three studies. Fluency was assessed by four studies, higher 
executive function tasks such as reasoning, pattern separation, and switching was 
assessed by five studies, and one study assessed participant impulsiveness. 
1.42 Assessment of Study Quality 
Quality was assessed using an amended version of the Checklist for Measuring 
Study Quality in Randomised Controlled Trials and Non-randomised Trials (See: Table 
1.2: Assessment of Study Quality). Studies were evaluated according to the quality of 
their reporting, their external validity, and their internal validity. For more detailed 
information see Appendix 1.D: Detailed Critical Appraisal of Included Studies. 
Reporting. To determine the quality of reporting, the clarity and transparency of 
the studies were examined. All studies clearly described their hypotheses, main 
outcomes, characteristics of participants, intervention of interest and principal 
confounders. Two studies did not report simple outcome data (Shiroma et al, 2014; 
Grunebaum et al, 2017), and four studies did not systematically measure and report 
adverse effects (LaPorte, 1996; Murman et al, 1997; Shiroma et al, 2014; Murrough et 
al, 2015). All but one study described characteristics of participants lost to follow up 
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(Galvez et al, 2018), and all but two also reported actual probability values (Zohar, 
2002; Galvez et al, 2018). 
Table 1.2 
Critical Appraisal of Studies by Quality of Reporting, External Validity, Bias and 
Confounding  
Study 
 
(Maximum score) 
Reporting  
 
(11) 
External 
Validity  
(3) 
Internal Validity  
– Bias 
(7) 
Internal Validity 
– Confounding   
(6) 
1996, LaPorte et al 10 0 7 3 
1997, Mahotra et al 11 0 7 4 
1997, Murman et al 10 1 7 6 
2001, Reeves et al 11 2 5 4 
2002, Zohar et al 10 2 4 4 
2008, Aubrun et al 11 1 6 6 
2014, Shiroma et al 9 0 5 2 
2015, Murrough et al 10 0 7 3 
2017, Grunebaum et al 10 0 6 5 
2018, Galvez et al 9 0 7 3 
External validity. The external validity of most included studies was poor, and so 
it is difficult to generalise their results to other situations or people. No studies reported 
how many potential participants were approached, or whether the distribution of 
confounding factors in participants was similar to the distribution of those factors in the 
study’s sample or in the source population.  In addition, of the 10 studies included, only 
four were completed at locations which would normally treat patients with the 
diagnosed problems (Murman et al, 1997; Reeves et al, 2001; Zohar, 2002; Aubrun et 
al, 2008).  Further damaging external validity, only 2 studies ensured that participants 
were representative of the source population, by approaching all appropriate potential 
participants in a particular service during a prescribed time frame (Reeves et al, 2001; 
Zohar, 2002). 
Bias. Eight studies were double blinded, and two reported no form of blinding 
(Reeves et al, 2001; Shiroma et al, 2014). It did not appear that any study results were 
based on ad-hoc analysis. It was not possible to identify any statistical adjustments 
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made for differing follow-up times between participants in one study (Zohar, 2002), 
however for all others the follow up was the same or analysis was adjusted for differing 
follow-up times. Compliance with treatment appeared reliable for all studies as there 
was no mention of non-compliance, and statistical testing appeared appropriate for all 
but two studies for which the reviewer was unable to determine appropriateness (Zohar, 
2002; Aubrun et al, 2008). Finally, while it was not possible to determine the validity 
and reliability of outcome measures used in two studies (Zohar, 2002; Grunebaum et al, 
2017), outcome measures were clearly described in the remaining eight. 
Confounding. There appeared to be a high risk of selection bias in several 
studies. It was not possible to determine if cases and controls were recruited from the 
same population in three studies (Murrough et al, 2015; Grunebaum et al, 2017; Galvez 
et al, 2018), and not possible to determine if cases and controls were recruited over the 
same time period for seven (LaPorte et al, 1996; Malhotra et al, 1997; Reeves et al, 
2001; Zohar, 2002; Shiroma et al, 2014; Murrough et al, 2015; Galvez et al, 2018). 
Three studies did not randomise participants to interventions. One study used a within-
subjects design (Shiroma et al, 2014), one did not report their method of randomisation 
(Murrough et al, 2015), and one used alternate allocation to treatment (LaPorte et al, 
1996). Four of ten studies either did not adjust analysis for confounding factors or did 
not report doing this (LaPorte et al, 1996; Zohar, 2002; Shiroma et al, 2014; Galvez et 
al, 2018). However, all studies reported taking missing data or participant 
discontinuation into account during the analysis. 
1.43 The Effect of Ketamine on Cognitive Function 
The neuropsychological tasks used, and the effect of ketamine on cognitive 
function for each of the review articles is outlined in Table 1.3 (Details of 
Neuropsychological Tasks Used in Included Studies). 
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Table 1.3. 
Details of Neuropsychological Tasks Used in Included Studies 
1a. Patients with a medical diagnosis 
Study Details 
 
Neuropsychological 
Task 
Task Procedure  Domain Reported Results 
1997 
Murman et al 
 
Medical – Huntington’s Disease 
 
Two within-subjects 
groups: 
1. IV ketamine: Escalating 
doses: 0.10, 0.40 & 0.60 
mg/kg/hr  
2. IV placebo 
 
Test Procedure: 
All tests repeated 20 min post dose 
change 
 
(NB: measures of attention and motor 
agility used to monitor for sedative/ 
anaesthetic effects of ketamine or the 
development of fatigue) 
 
Buschke Selective 
Reminding Test 
Participants learn a list of 12 related words that 
are presented in six trials, during which 
subjects are selectively reminded of forgotten 
words. Immediate recall is measured initially, 
and delayed recall measured 30 minutes later.  
Memory, Verbal – 
Immediate & 
Delayed 
At the 0.4 dose of ketamine 
immediate verbal memory, 
delayed visual memory & 
verbal fluency was impaired 
 
At the 0.6 dose immediate 
visual memory, 
psychomotor  
agility and one measure of 
attention (reaction time) 
was impaired 
 
Delayed verbal memory and 
attention (digit span) was 
not affected by ketamine in 
any dose 
Washington Square 
Picture Memory Test 
Immediate and delayed recognition of pictures 
of common objects 
Memory, Visual – 
Immediate & 
Delayed 
Letter Fluency  Participants given one minute to generate 
words in response to a stimulus letter. Alternate 
consonants of comparable difficulty used with 
each drug administration 
Verbal Fluency, 
Semantic Memory 
& Executive 
Cognitive Skills  
Digit Span Forward  Pairs of lists of numbers are read aloud, each 
pair of lists is one digit longer than the 
previous pair. Participants repeat the lists of 
numbers. 
Attention 
Reaction Time, Simple  Time in milliseconds required to respond 
verbally to a visual cue 
Attention 
Finger Tapping The average number of finger taps performed 
in 30 seconds during three trials with each 
hand. 
 
Motor Agility 
2001 
Reeves et al 
 
Medical – Post-Surgical Pain 
 
Trail Making Test A & 
B 
 
Participants asked to connect circles as quickly 
as possible: 
 
A: participants connect circles with numbers in 
them in increasing order 
Attention & 
Perception 
Psychomotor agility with 
switching significantly 
impaired in morphine & 
ketamine group (P=0.037) 
 
35 
 
Two between-subjects groups: 
1. IV ketamine & morphine 
(patient controlled). Ketamine 
1 mg/ml + morphine 1 mg/ml 
2. IV morphine (patient 
controlled). Morphine 1 
mg/ml 
 
Test Procedure: 
Baseline (pre-op) & at 48h post-op  
 
 
B: circles connect both numbers and letters in 
increasing order 
2002 
Zohar et al 
 
Medical – Post-Surgical Pain 
 
Two between-subjects groups: 
1. Wound instillation of 
bupivacaine & ketamine 
(patient controlled). 0.125% 
bupivacaine & ketamine (1 
mg/mL) 
2. Wound instillation of 
bupivacaine (patient 
controlled). 0.125% 
bupivacaine.  
Ceiling of 9ml/hour. Rescue morphine 
if needed 
 
Testing Procedure: 
Baseline (pre-op), immediately post-
op, at 2 hour-intervals while in 
recovery & at 24h post-op  
 
Digit Symbol 
Substitution Test 
(DSST) 
 
 
 
Participants are given a matrix with matching 
digits and symbols. They are then given a page 
of digits and are asked to write the 
corresponding symbols below. 
Memory  No s.d.in cognitive 
functioning 
 
No s.d. in: 
Analgesia 
Use of drug 
Morphine consumed 
Pain satisfaction 
Mini-Mental State 
Examination (MMSE) 
Orientation: What is the (year, season, date, 
day, month)? & Where are we (state, country, 
town, hospital, floor)? 
Registration: Number of trials to learn a list of 
3 objects 
Attention: Serial sevens/ spell “world” 
backwards 
Recall: of word list previously presented 
Language: 6 tasks of ability to follow 
instructions 
Orientation 
Registration 
Recall 
Attention 
Language Fluency 
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2008 
Aubrun et al 
 
Medical – Post-Surgical Pain 
 
Two between-subjects groups: 
1. IV ketamine & morphine 
(patient controlled) - 
Morphine 1mg/mg & 
ketamine 0.5mg/ml 
2. IV morphine (patient 
controlled) - Morphine 
1mg/ml 
 
Testing Procedure: 
Baseline (pre-op); Immediately post-
op; Day 1 - a.m.; Day 2 - a.m.; Day 2 - 
p.m. 
Mini-Mental State 
Examination (MMSE) 
Orientation: What is the (year, season, date, 
day, month)? & Where are we (state, country, 
town, hospital, floor)? 
Registration: Number of trials to learn a list of 
3 objects 
Attention: Serial sevens/ spell “world” 
backwards 
Recall: of word list previously presented 
Language: 6 tasks of ability to follow 
instructions 
Orientation 
Registration 
Recall 
Attention 
Language Fluency 
No s.d. in cognitive 
functioning between 
ketamine & placebo 
 
No s.d. between pre- & 
post-op cognitive 
functioning 
 
No s.d. in: 
Pain relief 
Additional morphine 
Adverse effects 
Mood 
Digit Symbol 
Substitution Test 
(DSST) 
 
Participants are given a matrix with matching 
digits and symbols. They are then given a page 
of digits and are asked to write the 
corresponding symbols below.  
Memory 
 
Digit Span (WAIS) – 
Forward & Backwards 
 
Pairs of lists of numbers are read aloud, each 
pair of lists is one digit longer than the 
previous pair. Participants repeat the list of 
numbers either in the same order or in the 
reverse order 
Working Memory 
 
 
1b. Patients with a psychiatric diagnosis 
Study Details 
 
Neuropsychological Task Task Procedure  Domain Reported Results 
1996 
LaPorte et al 
 
Psychiatric: Schizophrenia 
 
Two between-subjects groups: 
1. Injection of ketamine - 0.5 
mg/kg 
2. Injection of placebo  
 
Testing Procedure: 
Letter Fluency – 
Controlled Oral Word 
Association Test 
(Control Task 1) 
Participants are given one minute to generate 
words in response to each of three stimulus 
letters  
Verbal Fluency No significant drug vs 
placebo differences in 
cognition 
 
Learning score lower 
following ketamine 
administration (non-
significant) 
Category Fluency – 
Controlled Oral Word 
Association Test (Control 
Task 2) 
Participants given one minute to generate 
words in response to one of three stimulus 
categories (e.g. animals)  
Verbal Fluency 
Line Bisection (Control 
Task 3) 
Participants asked to bisect 20 offset lines of 
varying lengths 
Visuoperceptual 
Serial Digit Learning Participants learn a supraspan digit sequence 
(normal span + 2 digits) over 12 trials. 
Attention (Sustained) 
Learning 
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Pre-injection & 30-45min post-
injection 
 
[Authors note: “control tasks were 
administered at baseline and 30-45 
min post-injection… to rule-out 
generalized impairment”] 
Logical Memory 
(Wechsler Memory Scale-
Revised; Wechsler, 1987) 
Recall a short story immediately after it is read 
& and to repeat it again after 30-40 min 
Memory, Episodic 
Immediate & Delayed 
Figural Reproduction 
(Wechsler Memory Scale-
Revised; Wechsler, 1987) 
 
A figure is presented for 10 seconds after 
which the participant is asked to immediately 
reproduce it 
Memory, Visual 
1997 
Malhotra et al  
 
Psychiatric: Schizophrenia 
 
Two within-subjects groups: 
1. IV ketamine - Bolus of 0.12 
mg/kg of ketamine followed 
by 1hr infusion of 0.65 mg/kg 
of ketamine  (total dose of 
0.77 mg/kg/hr) 
2. IV placebo - Saline infusion 
of 1 hour 
 
Testing Procedure: 
Baseline at 30min pre-infusion; 
Repeated at 10min, 55min, 90min and 
120min post-infusion 
 
Word List Part 1 Participants read a list of 12 categorically 
related words. 6 words were read once, 6 were 
repeated. Participants were asked to say repeat 
when a word was repeated. 
Attention & Working 
Memory 
 
Ketamine impaired recall 
& recognition memory in 
healthy participants and 
those with a diagnosis of 
schizophrenia. 
 
Participants with a 
diagnosis of 
schizophrenia were 
significantly more 
impaired in recall than 
healthy participants 
Attention was not 
significantly impaired by 
ketamine in either group. 
Word List Part 2 Participants asked to recall the 12 previously 
presented words after a 2-minute delay. 
Memory, Verbal – 
Free Recall 
Word List Part 3 Participants were read a list of 12 distractor 
items and 12 previously presented words and 
asked to identify if each word was new or 
previously presented.  
Memory, Verbal – 
Recognition 
 
2014 
Shiroma et al 
 
Psychiatric: Treatment Resistant 
Depression 
 
One group: 
1. IV ketamine - 0.5 mg/kg 
ketamine HCl over 40 min 
per session. 6 sessions in two 
Identification Task Identify if the card presented is red Attention Significant improvement 
in simple & complex 
working memory and 
visual memory.  
 
These changes are n.s. 
when change in 
depression accounted for 
 
N-Back Task (1-Back; 2-
Back) 
 
Identify if a card presented is the same as the 
card before 
Identify if a card presented is the same as the 
one two cards before  
Working Memory 
 
Groton Maze Learning 
Test  
Find the hidden pathway in a 10x10 grid of 
tiles 
Working Memory - 
Spatial 
Continuous Paired 
Associate Learning Task 
Find the correct location of an object Memory, Visual 
 
One Card Learning Task  Identify if card has been seen before in a task Memory, Visual 
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weeks (Mon; Wed; Fri; Mon; 
Wed Fri) 
 
Testing Procedure: 
Pre-infusion baseline and after 
completion of all 6 infusions at each 
follow-up (week 3, 4, 5 & 6) 
Groton Maze Learning 
Test – Delayed Recall  
Remember the hidden pathway learned 
previously in a 10x10 grid of tiles 
Memory, Visual No s.d. in other cognitive 
domains 
International Shopping List 
Task  – Immediate Recall 
Remember items read from a shopping list Memory, Verbal – 
Immediate  
International Shopping List 
Task – Delayed Recall 
Remember items from a previously read 
shopping list 
Memory, Verbal – 
Delayed  
Groton Maze Change Test Chase a target in a 10x10 grid of tiles Processing Speed 
Detection Task Identify once a card is flipped over and face 
up 
Processing Speed 
Set-Shifting Task Identify whether a card is the target stimulus 
dimension (a colour or a number) 
 
Set Shifting 
(Executive Function) 
2015 
Murrough et al 
 
Psychiatric: Treatment Resistant 
Depression 
 
Two between-subjects groups: 
1. IV ketamine - Ketamine 0.50 
mg/kg over 40 min  
2. IV midazolam - Midazolam 
0.045 mg/kg over 40 min 
 
Testing Procedure: 
Within one week pre-infusion & at 7 
days post infusion 
Matrics Consensus Cognitive Battery:  Significant improvement 
in processing speed and 
verbal & visual learning 
in ketamine and 
midazolam groups  
(when controlling for 
change in depression 
 
No sig. effect of 
ketamine on cognition 
 
No sig. effect of anti- 
depressant response on 
cognition 
Trail Making Test A Participants connect circles with numbers in 
them in increasing order as quickly as possible 
Processing Speed 
 
Digit Symbol Substitution 
Test (DSST) 
(Brief Assessment of 
Cognition In 
Schizophrenia) 
Participants are given a matrix with matching 
digits and symbols. They are then given a 
page of digits and are asked to write the 
corresponding symbols below. 
Processing Speed 
 
Category Fluency Task Participants given one minute to generate 
words in response to a stimulus category 
Processing Speed 
Spatial Span (Wechsler 
Memory Scale) 
Duplicate a pattern after it has been 
demonstrated 
Working Memory 
 
Letter-Number Sequencing Participant is read a list of numbers and letters 
and must recall the numbers in ascending 
order and the letters in alphabetical order 
Working Memory 
 
Hopkins Verbal Learning 
Test (HVLT) – Learning 
and Delay Conditions 
Participants are read a 12-item list and asked 
to repeat it. There are 3 trials of this. After a 
delay, participants must to recall the words. 
They are then read a list of 24 words and 
asked to say if they were on the original list 
Verbal Learning 
 
Brief Visual Memory Test 
(BVMT) – Learning 
Conditions 
Participants are shown 6 geometric designs for 
10 seconds and asked to reproduce them. This 
is repeated 3 times. After a 30-minute delay, 
Visual Learning 
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participants are asked to reproduce the 6 
figures again. 
Mazes – 
Neuropsychological 
Assessment Battery 
 
Timed paper and pencil mazes of increasing 
difficulty 
Reasoning/Problem 
Solving 
 
2017 
Grunebaum et al 
 
Psychiatric: Bipolar Depression 
 
  
Two between-subjects groups: 
1. IV ketamine – racemic 
ketamine HCl 0.5 mg/kg 100 
mL of normal saline over 40 
minutes 
2. IV midazolam - midazolam 
0.02 mg/kg in 100 mL of 
normal saline over 40 
minutes 
 
Testing Procedure: 
At baseline & after testing 
Reaction Time, Simple 
(Computerised) 
Participants are shown a black screen with a 
square outlined in white. Participants are 
asked to press a key each time a red X is 
presented in the box. The X is presented after 
a randomised delay of 50-250ms. (Sackiem et 
al, 2001) 
Reaction Time Improved reaction time, 
attention and memory in 
both groups 
 
Reaction time improved 
more in midazolam 
group than ketamine 
 
Verbal fluency declined 
in ketamine vs 
midazolam groups on 
day 1 
Ketamine: Poor baseline 
memory encoding 
correlated with 
improvement in HDRS-
17 and SSI. 
 
Ketamine: Increased 
memory (SRT) at day 1 
correlated with reduction 
in HDRS-17 and 
reduction in SSI. 
Midazolam: Poor 
baseline memory 
correlated with reduction 
in HDRS-17 & SSI at 
day 1. 
Reaction Time, Choice 
(Computerised) 
Participants are shown a black screen with 
four squares outlined in white laid out in a 
windowpane pattern. A red X appears in one 
box and participants are asked to hit the key 
corresponding to the box with the X in it. A 
new layout of boxes is presented every 50ms. 
(Sackiem et al, 2001) 
Reaction Time 
Digit Symbol Substitution 
Test (DSST) (WAIS III) 
Participants are given a matrix with matching 
digits and symbols. They are then given a 
page of digits and are asked to write the 
corresponding symbols below. 
Processing Speed 
Trail Making Test A & B Participants asked to connect circles as 
quickly as possible: 
 
A: participants connect circles with numbers 
in them in increasing order 
 
B: connect circles with both numbers and 
letters in increasing order 
Processing Speed 
Continuous Performance 
Test, Identical Pairs 
Version (Computerised) 
Participants are shown a series of 4-digit 
numbers and asked to indicate when the same 
4-digit number is shown twice in a row 
(Sackiem et al, 2001) 
Attention 
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Stroop (Computerised)  A stimulus is presented, and participants are 
asked to identify the name of or colour of the 
stimulus. Stimuli are colour names presented 
in that colour, X’s presented in different 
colours, and colour names presented in 
incongruous colours (Sackiem et al, 2001) 
Attention Midazolam: Increased 
day 1 memory encoding 
related to reduction in 
HDRS-17 and SSI 
Buschke Selective 
Reminding Test 
Participants are given a list of 12 words and 
immediately asked to recall them over 6 trials. 
They are reminded only of words they did not 
recall during the previous trial. They are asked 
to free recall the entire list after 30 minutes 
(Sackiem et al, 2001). 
Memory 
Benton Visual Retention 
Test, Administration D 
Participants are exposed to 10 designs for 10 
seconds each. They are asked to reproduce the 
design after a 15 second delay (Sackiem et al, 
2001) 
Memory 
A Not B Reasoning 
(Computerised)  
Participants shown a statement that describes 
the relationship between two letters. They are 
shown an arrangement of the two letters below 
the statement. They are asked to indicate if the 
statement is correct or not using yes/no keys 
(Sackiem et al, 2001) 
Working Memory 
N-Back Task 
(Computerised)  
Identify if a letter presented is the same as the 
one before (1-back), the one two letters before 
(2-back) or the one three letters before (3-
back) (Sackiem et al, 2001) 
Working Memory 
Letter Fluency – 
Controlled Oral Word 
Association Tests 
Participants are given one minute to generate 
words in response to a stimulus letter (Keilp et 
al, 2005) 
Language Fluency 
Category Fluency – 
Controlled Oral Word 
Association Tests 
(Animals) 
Participants given one minute to generate 
words in response to a stimulus category 
(Keilp et al, 2005) 
Language Fluency 
Go-No Go (Computerised) Participants are shown a letter X on one of 6 
locations on the computer screen. They are 
simultaneously played a high or low tone. 
Impulsiveness 
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They are instructed to hit a response key when 
the X appears in the top half of the screen and 
is accompanied by a low tone (Keilp et al, 
2005). 
Time Production 
(Computerised) 
A beep is sounded, and participants are given 
a time interval – they are asked to press a key 
when they think that interval of time has 
passed (Keilp et al, 2005). 
 
Impulsiveness 
2018 
Gálvez et al 
 
Psychiatric: Treatment Resistant 
Depression 
 
Two between-subjects groups: 
1. Intranasal ketamine - ten 
sprays of 100 mg of ketamine 
(ketamine HCl 200 mg/2 mL, 
Ketalar®). 3/week for 2 
weeks, weekly for 2 weeks 
2. Intranasal midazolam - ten 
sprays of 4.5 mg midazolam 
(midazolam HCl, Hypnovel® 
5 mg/mL, diluted with 0.9% 
saline). 3/week for 2 weeks, 
then weekly for 2 weeks 
 
Testing Procedure: 
Baseline & at 48–72 hr after treatment 
course 
Identification Task Identify if the card presented is red Reaction Time 1 ketamine participant 
sig. impaired in reaction 
time 
1 midazolam participant 
sig. impaired in working 
memory 
Detection Task  Identify once a card is flipped over and face 
up 
Reaction Time 
N-Back Task (2-Back 
Task) 
Identify if a card presented is the same as the 
one two cards before (complex working 
memory) 
Working Memory 
International Shopping List 
Task  
Remember items from a previously read 
shopping list 
Memory, Verbal – 
Immediate & Delayed 
One Card Learning Task Identify if card has been seen before in a task Memory, Visual  
Set-Shifting Task Identify whether a card is the target stimulus 
dimension (a colour or a number) 
Set-Shifting 
(Executive Function) 
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In medical use. Four studies explored the effects of ketamine on cognitive 
functioning in a medical context.  
Pain. One study of acute post-operative pain (Reeves et al, 2001) found no 
significant psychomotor agility differences for participants receiving IV ketamine and 
morphine versus those receiving IV morphine alone. However, they did find that a task 
of psychomotor agility with switching was significantly impaired in the morphine and 
ketamine group.  
 There were no differences in pre-and post-operative cognitive functioning 
between participants given IV ketamine plus morphine and those given IV morphine 
alone, and no significant differences in cognitive functioning between the two groups 
(Aubrun et al, 2008). However, this study reported that the Digit Symbol Substitution 
Task (DSST) was a measure of memory, and while this study used the same dose of 
morphine as the previous, it administered a lower dose of ketamine.  
Finally, participants receiving ketamine plus bupivacaine or bupivacaine alone via 
wound infiltration found no significant differences in domains of attention and 
switching, or in the domains of orientation, attention, memory and language functioning 
(Zohar, 2002).  
Huntington’s disease. Participants with Huntington’s disease (Murman et al, 
1997) given a moderate dose of ketamine found that immediate verbal memory, delayed 
visual memory, and performance in a verbal fluency task were impaired. At a high 
ketamine dose, immediate visual memory, psychomotor agility, and attention were 
impaired. Performance on tasks of delayed verbal memory and another task of attention 
was not affected by ketamine in any dose. 
In psychiatric use. Six studies explored the effects of ketamine on cognitive 
functioning in a psychiatric context.  
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Schizophrenia. Two studies explored the cognitive ramification of ketamine in 
participants with schizophrenia. One study administered ketamine via IV infusion in 
people with a diagnosis of schizophrenia and healthy controls (Malhotra et al, 1997), 
while the other administered injections of ketamine in participants with a diagnosis of 
schizophrenia (LaPorte et al, 1996).  
Participants with a diagnosis of schizophrenia injected with ketamine experienced 
no drug effect in domains of episodic verbal memory or visual memory, and there were 
no differences in retention of episodic memory between drug and placebo (LaPorte et al, 
1996). Performance in tasks of letter and category fluency were not affected by 
ketamine, and there was no significant difference pre and post drug for either group of 
participants. Visuoperceptual performance was also not affected by ketamine, and again 
there was no significant difference pre and post drug for either group (LaPorte et al, 
1996). Though non-significant, there was some evidence of learning impairment in the 
ketamine group (LaPorte et al, 1996). 
Participants with a diagnosis of schizophrenia and healthy controls administered 
IV ketamine experienced no differences in attention among the four groups (people with 
a diagnosis of schizophrenia; healthy participants; ketamine; placebo) (Malhotra et al, 
1997). There was impairment in recall and recognition memory in participants with a 
diagnosis of schizophrenia and healthy participants receiving ketamine, and a 
significant impairment in recall for participants with a diagnosis of schizophrenia as 
compared to healthy participants (Malhotra et al, 1997).  
Depression. Four studies looked at the cognitive ramifications of ketamine in 
various types of depression.  
 Bipolar depression. Though participants with bipolar depression administered 
IV midazolam, or midazolam and ketamine exhibited higher than average intelligence, 
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baseline reaction time, baseline memory and baseline language fluency was below the 
population average for both groups (Grunebaum et al, 2017).  
Attention increased in both groups after drug administration, as did reaction time 
and memory. Reaction time was more improved in the midazolam group than in the 
ketamine group. After drug administration, ketamine participants saw impairment in 
their language fluency performance; however the midazolam group did not. There were 
no significant group results in the domains of impulsiveness, working memory, or 
processing speed (Grunebaum et al, 2017). 
TRD. Participants receiving six sessions of IV ketamine over two weeks 
experienced significant improvements in one task of visual memory and in measures of 
simple working memory and complex working memory (Shiroma et al, 2014).  
However, two tasks of visual memory, showed no significant changes. In addition, tasks 
which measured attention, spatial working memory, immediate and delayed verbal 
memory, processing speed and the executive function of set-shifting, did not show 
significant changes after drug administration (Shiroma et al, 2014). 
Seven days after receiving an acute infusion of IV ketamine or IV midazolam, 
both groups of participants displayed improved cognitive function in the domain of 
processing speed (Murrough et al, 2015). There was significant improvement in visual 
and verbal memory, no change in working memory or problem solving, and there was 
no significant difference in the cognitive performance of either group post drug 
(Murrough et al, 2015). 
Finally, a small five participant trial which administered intranasal ketamine or 
intranasal midazolam over five weeks found impairment in reaction time for one 
participant receiving ketamine, and impairment in working memory for one participant 
receiving midazolam (Galvez et al, 2018). This study did not report differences in the 
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executive function of set shifting, or in the domains of visual or verbal memory (Galvez 
et al, 2018). 
1.44 Other Effects of Ketamine 
In medical use.  
Pain. Participants receiving patient-controlled IV morphine plus ketamine, or 
patient controlled IV morphine alone after major abdominal surgery saw no group 
differences in their pain intensity at rest or on movement, their assessment of analgesic 
efficacy, or their overall opioid consumption (Reeves et al, 2001). After a major 
gynaecological surgery, there were no group differences in pain relief, opioid 
consumption, adverse effects, or mood for participants receiving patient-controlled IV 
morphine plus ketamine, or patient controlled morphine alone (Aubrun et al, 2008). 
Finally, participants receiving patient-controlled wound infiltration of ketamine plus 
bupivacaine, or bupivacaine alone after caesarean section did not exhibit group 
differences in amount of drug self-administered, pain at rest or on movement, overall 
analgesic satisfaction or additional opioid consumption (Zohar et al, 2002). 
Huntington’s disease. Participants with Huntington’s disease were given low, 
medium and high doses of ketamine, as well as a placebo infusion on a separate day 
(Murman et al, 1997). At the high ketamine dose, incidence of adverse effects, 
psychiatric symptoms and worsening eye movements were significantly increased 
(Murman et al, 1997). 
In psychiatric use. 
Schizophrenia. Participants with a diagnosis of schizophrenia injected with 
ketamine experienced an acute increase in psychotic symptoms within 20 minutes of 
ketamine administration as compared to those administered a placebo (LaPorte et al, 
1996). Psychotic symptoms largely returned to baseline within 45 minutes post drug 
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administration (LaPorte et al, 1996). A study of people with a diagnosis of 
schizophrenia and healthy participants administered IV ketamine and IV placebo on two 
separate days found that ketamine increased psychotic symptoms in participants with a 
diagnosis of schizophrenia, but not in healthy controls (Malhotra et al, 1997). Ketamine 
administration did not lead to a change in anxiety or mood in either group (Malhotra et 
al, 1997). 
Depression. Participants with bipolar depression administered an IV infusion of 
ketamine had non-significantly lower suicidal thoughts compared to participants 
administered midazolam (Grunebaum et al, 2017). In the ketamine group, poor 
encoding of memory correlated with reduced suicidal thoughts (Grunebaum et al, 2017) 
Participants receiving six infusions of IV ketamine over two weeks in an 
uncontrolled trial saw a statistically significant reduction in depression symptoms 
(Shiroma et al, 2014). Low baseline attention was a predictor of decrease in depression 
severity, and of the likelihood that participants’ depression would respond to ketamine. 
Conversely, better performance in baseline verbal memory predicted a decrease in 
depression severity. Change in cognitive performance over the treatment period was 
accounted for by a reduction in depression severity, however, cognitive performance did 
not predict relapse over the four-week post-treatment follow-up period (Shiroma et al, 
2014).  
Participants with TRD receiving either IV ketamine or IV midazolam experienced 
similar antidepressant response regardless of drug administered (Murrough et al, 2015). 
As outlined in the cognitive effects section, processing speed, and visual and verbal 
learning improved in both groups, and this change remained significant when 
controlling for a reduction in depression. Participants whose depressive symptoms 
responded to ketamine administration had a slower baseline processing speed than those 
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who did not respond to ketamine. There was no association between cognitive 
performance and antidepressant response in midazolam participants (Murrough et al, 
2015). 
A study administering intranasal ketamine or midazolam over four weeks found 
that ketamine participants experienced more frequent dissociative symptoms and higher 
blood pressure than their midazolam counterparts (Galvez et al, 2018). This study also 
determined that variable absorption and tolerability are two drawbacks of using 
participant administered intranasal ketamine (Galvez et al, 2018). 
1.5 Discussion 
This review aimed to explore the cognitive effects of sub-anaesthetic ketamine 
used for psychiatric and medical problems. It also aimed to explore other effects of 
ketamine when used in these populations. This discussion will focus on the strengths 
and limitations of the studies selected, as well as on the effect of ketamine on cognition 
and on the various problems identified. 
1.51 Strengths and Limitations of Studies 
Assessment of Study Quality. This literature review aimed to look at studies 
which by virtue of their population of patients receiving treatment would be more 
externally valid than studies using healthy volunteers. However, the external validity of 
the studies, as measured by the Downs & Black (1998) checklist was low. This is 
because many studies did not report the ratio of participants to source population, did 
not report the number of participants who declined to participate, did not report the time 
frame during which recruitment was ongoing, or treated participants at specialist or 
inpatient research facilities. 
As outlined in the results section, the quality of reporting in most of the selected 
studies was high. All studies ensured that participants were complaint with prescribed 
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interventions, were statistically appropriate, and none reported results based on ad-hoc 
analysis. In addition, all studies reported using intent to treat analysis, and most studies 
randomised participants to treatment condition and then concealed this from participants 
and staff. However, it was difficult to determine if active and control participants were 
recruited from the same population or over the same time period as this was largely 
unreported. Further, almost half of the studies did not adjust for potential confounds 
Measures of Cognitive Function. Most studies used standardised, clearly 
described measures of cognition. Indeed, most neurocognitive tasks used were sensitive 
to small levels of change and therefore appropriate for measuring differences in pre and 
post drug functioning. However, two studies used the Mini-Mental State Examination to 
measure changes in cognitive function before, during and after administration of 
ketamine in participants post-surgery (Aubrun et al, 2008; Zohar et al, 2002).  The 
Mini-Mental State Examination is a 0-30 item which measures orientation, registration, 
recall, attention and language fluency, and is widely used as a screening measure for 
identifying dementia and mild cognitive impairment (Arevalo-Rodriguez et al, 2015). 
The simplicity of the task, its floor and ceiling effects, and its low sensitivity to change 
(Philipps et al, 2014) means that this is not appropriate for measuring potentially small 
pre and post drug cognitive changes. 
A major issue with the studies was related to reporting domains associated with 
neurocognitive tasks. Cognitive domains are not rigidly separate categories, and 
neurocognitive tasks are often a predictor of functioning in multiple domains. However, 
several studies used the same neurocognitive task but reported that the task measured 
different cognitive domains. Four studies used the Digit Symbol Substitution Test 
(DSST) as a measure of cognition. The DSST measures perceptual and processing 
speed, as well as memory and motor speed to a lower degree (Laux & Lane, 1985). 
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Performance in this task is also associated with learning, and with working memory 
(Jaeger & Zaragoza Domingo, 2016). While two of the four studies reported that the 
DSST is a measure of memory (Aubrun et al, 2008; Zohar et al, 2002), the other two 
reported that it is a measure of processing speed (Grunebaum et al, 2017; Murrough et 
al, 2015). 
Three studies used the Trail-Making Task A and B. This task has been evaluated 
to be a measure of psychomotor speed (Trails A) and of executive function and 
psychomotor speed (Trails B) (Salthouse, 2011). One study reported that it is a task of 
psychomotor speed and switching (a task of executive function) and also that the task is 
a measure of attention and perception (Reeves et al, 2001). Another study reported 
Trails A as a measure of psychomotor speed (Murrough et al, 2015), and one reported 
that Trails A & B both measure psychomotor speed only (Grunebaum et al, 2017). 
Tasks involving letter (phonemic) and category (semantic) fluency also showed 
variations in the reporting of their underlying domains. Research indicates that 
executive control and verbal ability (semantic memory) are predictors of performance 
on both fluency tasks (Shao, Janse, Visser & Meyer, 2014), and that phonological 
fluency appears to be more related to executive function, while semantic fluency 
appears to be more related to semantic memory (Crawford, Vennero & O’Carroll, 
1998). In addition, more recent research indicates that the tasks are significantly more 
related to language than they are to executive functioning (Whiteside et al, 2016). 
However, the studies that used phonological fluency tasks reported that the same task 
measured verbal fluency (LaPorte et al, 1996), language fluency (Grunebaum et al, 
2017) or a combination of verbal fluency, semantic memory and executive cognitive 
skills (Murman et al, 1997). The three semantic fluency tasks were reported as either 
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measures of verbal fluency (LaPorte et al, 1996), language fluency (Grunebaum et al, 
2017) or processing speed (Murrough et al, 2015). 
1.52 Ketamine’s Effect on Cognitive Functioning 
The 10 studies reviewed all looked at the cognitive effects of acute sub-
anaesthetic ketamine used for medical and psychiatric patients. However, the amount of 
between study variations introduced a level of difficulty when comparing study results. 
As outlined in the results section, studies varied by dose and type of ketamine 
administered, route of drug administration, use of an active or placebo control, 
neurocognitive tasks used, population characteristics, test settings, and time between 
ketamine administration and neurocognitive testing. Because of these study variations, 
it is not possible to draw a single conclusion about the effect of sub-anaesthetic 
ketamine on domains of cognition. However, an outline of cognitive trends by study 
context can be discussed.  
Previous research has indicated that in healthy participants, an acute dose of sub-
anaesthetic ketamine has little impact on executive functioning and does not appear to 
impair simple reaction time or either simple attention or selective attention as compared 
to baseline performance or to placebo (Hayley et al, 2017; Morgan & Curran, 2006). It 
also appears to impair episodic memory of information learned under the influence of 
the drug but not information learned prior to administration, the manipulation but not 
the maintenance of information in working memory, and the processing of semantic 
memory (Honey et al, 2003; Koychev, Deakin, El-Deredy, & Haenschel, 2017, Morgan 
& Curran, 2006; Morgan et al, 2004b). More relevant to this review, pain patients 
receiving long term ketamine had impairments in attention, working memory, semantic 
memory, and psychomotor coordination (Kim, Cho & Lee, 2016). In depressed patients, 
ketamine may lead to improvements in visual memory and simple and complex working 
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memory by virtue of its anti-depressant properties and participants with low pre-
ketamine attention and processing speed may be more likely to see a mood response to 
ketamine (Lee et al, 2016). 
In medical use. A study focused on the effect of ketamine on pain as compared 
to an active control found impairment in a task of psychomotor agility with switching in 
the ketamine group (Reeves et al, 2001). It is important to note here, that psychomotor 
agility was measured in this study with the Trail Making task, which is often reported to 
measure several different cognitive domains. There was no difference in the domains of 
orientation, attention, psychomotor agility, working memory, language functioning, or 
the executive function of switching in this or either of the other studies of ketamine for 
pain (Zohar, 2002; Aubrun et al, 2008). However as outlined above the Mini Mental 
State Examination may not have been a sensitive enough instrument to pick up subtle 
differences in cognitive functioning. 
Only one study explored the effects of ketamine in patients with Huntington’s 
disease (Murman et al, 1997). This study found no cognitive impairment at a low dose 
of ketamine, impairments in immediate verbal memory, delayed visual memory and 
verbal fluency tasks at a moderate dose of ketamine, and impairments in immediate 
visual memory, psychomotor agility and attention at a high dose of ketamine. In 
addition, delayed verbal memory and one measure of attention was not affected by 
ketamine at any dose (Murman et al, 1997). While verbal fluency has not been found to 
be impaired by ketamine in healthy participants, a 2005 neuroimaging study by Fu et al 
did see disruption in more difficult fluency tasks. 
In psychiatric use. A study of the effects of ketamine on participants with a 
diagnosis of schizophrenia found no difference in ketamine and placebo in the domain 
of visuoperceptual performance, or on tasks of letter and category fluency (LaPorte et 
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al, 2016). There was no impairment of visual memory, or of performance on or 
retention of episodic verbal memory, however, in line with previous research there was 
a trend towards learning impairment in ketamine participants (LaPorte et al, 2016). In 
addition, a study of the effects of ketamine and placebo on participants with a diagnosis 
of schizophrenia and healthy participants found no difference in attention between the 
groups but found that ketamine impaired recall and recognition memory in both 
participants with a diagnosis of schizophrenia and healthy participants (Malhotra et al, 
1997). Participants with a diagnosis of schizophrenia were significantly more impaired 
than healthy participants (Malhotra et al, 1997).  
A review of the cognitive ramifications of depression indicated that psychomotor 
speed, memory, attention and executive functioning are typically impaired in depressed 
patients (Lee, Hermens, Porter & Redoblado-Hodge, 2012). In line with this, a study of 
ketamine and bipolar depression found that participants receiving an acute infusion of 
IV midazolam or IV midazolam plus ketamine had lower baseline reaction time, 
memory and language fluency than the general population (Grunebaum et al, 2017). 
Attention, reaction time and memory improved post drug administration in both groups, 
however the midazolam group saw more improvement in reaction time. Language 
fluency was improved post drug in the ketamine group, but not the midazolam group. 
Finally, impulsiveness, working memory and processing speed was unchanged from 
baseline (Grunebaum et al, 2017). In the ketamine group, poor encoding of memory 
correlated with reduced suicidal thoughts (Grunebaum et al, 2017). 
An uncontrolled study administering six infusions of ketamine over two weeks 
found improvements in a task of visual memory and in simple and complex working 
memory (Shiroma et al, 2014). Other tasks of visual memory, and tasks of attention, 
spatial working memory, immediate and delayed verbal memory, processing speed and 
53 
 
the executive function of set-shifting were unchanged (Shiroma et al, 2014). Low 
baseline attention was a predictor of decrease in depression severity, and of the 
likelihood that participants’ depression would respond to ketamine, and better 
performance in baseline verbal memory was a predictor of decrease in depression 
severity. Change in cognitive performance over the treatment period was accounted for 
by a reduction in depression severity, however, cognitive performance did not predict 
relapse over the four-week post-treatment follow-up period (Shiroma et al, 2014).  
A week after administration of IV ketamine or IV midazolam, processing speed 
and visual and verbal memory was improved in both groups (Murrough et al, 2015). 
There was no change in working memory or problem solving, and no difference in 
cognitive performance by drug (Murrough et al, 2015). As outlined in the cognitive 
effects section, processing speed, and visual and verbal learning improved in both 
groups, and this remained so when controlling for a reduction in depression. 
Participants whose depressive symptoms responded to ketamine administration had a 
slower baseline processing speed than those who did not respond to ketamine. There 
was no association between cognitive performance and antidepressant response in 
midazolam participants (Murrough et al, 2015). 
Finally, reaction time for one ketamine participant and working memory for one 
midazolam participant was impaired in a small study using an intranasal route (Galvez 
et al, 2018). There was no difference in executive function or in visual or verbal 
memory (Galvez et al, 2018). 
1.53 Other Effects of Ketamine 
In medical use. This review indicated that ketamine does not appear to effect a 
reduction in opioid consumption or to provide an increased analgesic effect when added 
to commonly used analgesics in participants with acute post-surgical pain. However, 
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while previous research has argued ketamine is effective in treating post-surgical pain, 
most studies appear to indicate that ketamine is most effective in the treatment of 
chronic neuropathic pain conditions (Bell, 2009; Nourouzi et al, 2010; Subramaniam, 
Subramaniam & Steinbrook, 2004; Visser & Schug, 2006). In addition, it is possible 
that adding ketamine to another analgesic may have somewhat masked both its pain 
controlling and opioid reducing effects. Further studies comparing common analgesics 
to an administration of ketamine alone need to be conducted to fully evaluate its 
analgesic properties.  
Huntington’s is an incurable neurodegenerative disease which leads to changes in 
motor function, psychiatric function and cognitive ability (Dale & van Duijn, 2015). 
Researchers have theorised that the excitotoxin quinolinic acid may be a useful 
behavioural model of Huntington’s as it creates similar lesions in the brain (Jiang, 
Büchele, Papazoglou, Döbrössy, Nikkhah, 2009). Ketamine anaesthesia appears to 
disrupt these lesions created by quinolinic acid when administered to rats (Jiang et al, 
2009). This may begin to explain the results of this review, which indicated that 
participants with Huntington’s disease administered sub-anaesthetic ketamine 
experienced increased eye movements and psychiatric symptoms, however there is little 
further research on Huntington’s and ketamine. 
In psychiatric use. This review found that participants with a diagnosis of 
schizophrenia administered sub-anaesthetic ketamine saw an increase in psychotic 
symptoms, and that healthy controls did not experience psychosis (LaPorte et al, 2016; 
Malhotra et al, 1997). In line with these results, researchers have used the glutamate 
increase caused by ketamine as a model for schizophrenia and found that healthy 
participants were unaffected by a dose at which participants with a diagnosis of 
schizophrenia experience increased psychosis (Etkin, 2016). 
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This review indicated that ketamine appears to be as effective in the short-term 
amelioration of treatment resistant depressive symptoms, bipolar depression, and 
suicidal ideation as more established anti-depressant drugs. This is in line with previous 
research indicating that ketamine’s modulation of the NMDA receptor is useful in the 
treatment of previously intractable depression (Abdallah et al, 2015; Berman et al, 
2000; Fond et al, 2014; Lara et al, 2013; Matthews et al, 2012). 
1.54 Limitations and Conclusions 
Despite the very different characteristics of the reviewed studies, results appeared 
to triangulate with previous literature. In medical patients, acute sub-anaesthetic 
ketamine appears to affect memory - memory for information presented under the 
influence of the drug is impaired, as is the manipulation of information in working 
memory. Ketamine does not appear to decrease opioid use, or decrease pain when added 
to commonly used analgesics, however it is important that future research focus on the 
impact of ketamine alone on acute pain and ketamine alone on chronic neuropathic pain. 
In participants with depressive disorders, ketamine appears to improve memory, 
reaction time, and attention; however these effects are often accounted for by the 
antidepressant properties of the drug. In addition, poor baseline processing speed, 
memory and attention appear to be correlated to a decrease in depressive symptoms 
post-treatment. Ketamine appears to be as effective as active control when administered 
as an IV, however further research on the efficacy of intranasal ketamine is needed. 
 Limiting this review is the small number of available studies focusing on the 
cognitive effects of acute sub-anaesthetic ketamine in non-healthy participants. Further 
research on ketamine used for patients with medical and psychiatric problems is 
essential to truly understand the cognitive effects of the drug.  
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2.1 Abstract 
Aims: The study aimed to describe the relationships between cognitive functioning and 
acute pain relief in patients receiving acute sub-anaesthetic intravenous ketamine, and 
those receiving acute lidocaine as part of routine treatment for chronic pain. 
Method: This non-randomised, between subjects, active control study measured 
participant pain and cognitive performance before and after drug administration. Pain 
was measured using visual analogue scales of pain intensity, distress and interference. 
Cognition was measured using the Story Recall subtest of the Rivermead Behavioural 
Memory Test, a serial sevens subtraction task and a verbal fluency task. Data was 
analysed using mixed ANOVAs, and as data appeared non-parametric, Mann-Whitney 
tests were used to confirm results. Secondary data analysis involved investigating 
correlations among pain and cognitive domains. 
Results: 58 statistically similar participants completed the study: 34 received lidocaine 
and 24 received ketamine. Ketamine was significantly more effective than lidocaine in 
acutely reducing pain intensity and interference. Both groups had significantly 
improved verbal fluency post drug administration. As compared to lidocaine, ketamine 
significantly impaired post-drug serial seven performance and story recall performance 
for information learned under the influence of the drugs.   
Conclusions: Ketamine was effective in reducing acute pain, and impaired working 
memory, and the recall of information learned under drug influence. Results are 
discussed in relation to previous literature, and study limitations are discussed.  
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2.2 Introduction 
This study investigates the effects of acute sub-anaesthetic ketamine infusion on 
pain and cognitive functioning in participants with chronic neuropathic pain, using 
similar participants receiving acute lidocaine infusions as active control. This 
introduction describes the relationships between ketamine, pain and cognition according 
to published literature.  
2.21 Ketamine 
Ketamine is a non-competitive antagonist of the N-methyl-d-aspartate (NMDA) 
receptor, first synthesised in 1962 as a replacement human anaesthetic for phencyclidine 
(PCP). Because it does not impair spontaneous respiration or block the airways and 
works to produce both amnesia and analgesia when used for anaesthetic purposes, it has 
been a part of the World Health Organisation’s (WHO) Essential Medicines List since 
1985 (WHO, 2016). The WHO Expert Committee on Drug Dependence indicates that 
while ketamine is used recreationally worldwide, and that chronic recreational use can 
cause adverse side effects, the medical usefulness of the drug is such that it should not 
be controlled under international drug control conventions (WHO, 2016).  
There has been increased research interest in the use of medical ketamine for 
treating pain. EMBASE database searches for “ketamine and pain” returned close to 
3000 results from the period 1998-2008, but close to 5000 results from the period 2008 
to 2018. However, as outlined in the previous literature review, searching for clinical 
trials which assess the cognitive effects of acute sub-anaesthetic ketamine in non-
healthy participants returned only ten relevant studies.  Only three pain studies were 
found, and all administered ketamine to post-surgical patients alongside another 
analgesic agent. As there is a dearth of information regarding the cognitive effects of 
ketamine in pain, more research is needed.  
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2.22 Pain 
Pain is a complex phenomenon described by The International Association for 
the Study of Pain (IASP) as ‘‘an unpleasant sensory or emotional experience associated 
with actual or potential tissue damage or described in terms of such damage’’ (IASP, 
Task Force on Taxonomy, 1994). More recent discourse highlights the importance of 
cognitive and social aspects of pain, describing pain as “a distressing experience 
associated with actual or potential tissue damage with sensory, emotional, cognitive, 
and social components” (Williams & Craig, 2016). 
This study looks at participants experiencing chronic neuropathic pain. 
Neuropathic pain, as defined by the IASP, is that pain which is “initiated or caused by a 
primary lesion or dysfunction in the nervous system” and can refer to pain affecting the 
peripheral or central nervous system (IASP, Task Force on Taxonomy, 1994). Chronic 
pain is that which has been experienced for six months or more (IASP, Task Force on 
Taxonomy, 1994).  
When evaluating the efficacy of interventions on pain, measurement of pain 
change alone is not sufficient - physical and emotional functioning, participant ratings 
of improvement and satisfaction with treatment, symptoms and adverse events, and 
participant disposition should also be considered (Turk et al, 2003). Indeed, NICE 
guidelines on the pharmacological management of neuropathic pain recommend that 
regular clinical reviews focus on monitoring pain reduction, daily activities and 
participation, patient mood, overall patient rating of improvements, adverse effects, and 
finally, quality of sleep (NICE, 2011). 
Pain and ketamine. When used as an anaesthetic, ketamine also provides an 
analgesic effect (WHO, 2016). Indeed, anaesthetic doses of ketamine lead to pain 
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reduction and functional increase in participants with the chronic neuropathic illness 
complex regional pain syndrome (CRPS) (Keifer et al, 2008).  
A 2004 review exploring sub-anaesthetic ketamine adjuvant to an opioid for 
pain relief found that administration of a bolus of, or IV infusion of ketamine decreased 
opioid requirements in about half of the clinical trials reviewed but did not lead to a 
significantly greater pain reduction than the opioid alone (Subramaniam, Subramaniam 
& Steinbrook, 2004). However, a 2017 review indicated that an acute dose of sub-
anaesthetic ketamine does appear to lead to pain reduction as well as to a decrease in 
morphine consumption in participants with opioid-resistant cancer pain (Bell, Eccleston 
& Kalso, 2017).  
Research on participants receiving patient controlled sub-anaesthetic ketamine 
for acute post-surgical pain indicated little benefit of adding the drug to other analgesics 
(Aubrun et al, 2008; Reeves et al, 2001; Zohar et al, 2002). However, ketamine appears 
to have analgesic properties for chronic neuropathic pain participants at a sub-
anaesthetic dose, though degree of pain reduction varies between participants (Visser & 
Schug, 2006). 
2.23 Cognitive Function 
Cognition can be broadly defined as the way in which the brain acquires, 
processes, stores and retrieves information (Lawlor, 2002).  
Cognitive function and ketamine. Concerns about the use of acute non-
anaesthetic IV ketamine in treatment for chronic pain stem from research indicating that 
frequent recreational ketamine users show impairment in cognitive functioning. A 
review by Visser & Schug (2006) indicated that long term recreational ketamine users 
experience severe impairment of working, episodic and semantic memory. Additionally, 
a more recent review by Morgan and Curran (2011) indicated that frequent recreational 
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ketamine users have impairments in short and long-term memory, alongside disruption 
of visual recognition and impairments in spatial working memory.  
A one-year longitudinal study of recreational ketamine users showed decreases 
in spatial working memory and in pattern recognition memory (Morgan, Muetzelfeldt, 
Curran, 2010). Finally, a study involving patients with complex regional pain syndrome 
found that participants who had ketamine infusions twice a month for six months 
performed significantly worse on measures of attention, working memory, psychomotor 
coordination, and semantic memory than those who never or infrequently received 
ketamine (Kim, Cho & Lee, 2016).  
It is important to note that the controlled acute non-anaesthetic use of a drug can 
often have very different consequences than those associated with frequent recreational 
use. While there appear to be significant cognitive consequences related to long term 
recreational use of ketamine, there is less definitive evidence on the effect of acute sub-
anaesthetic intravenous doses of ketamine. 
In a 2006 review of ketamine and cognition, Morgan and Curran reported that 
episodic memory is impaired for information learned on ketamine, but not for recall of 
information learned before drug administration. The processing of semantic memory 
may be impaired, and as ketamine may also impair procedural learning, it can be 
suggested that ketamine may impair the encoding of information into memory (Morgan 
& Curran, 2006). It was unclear if sustained attention was impaired, simple attention 
and selective attention was largely unimpaired by the drug, and there was little impact 
on tasks of executive function once memory deficits were controlled for (Morgan & 
Curran, 2006). Finally, the maintenance of information in working memory appears to 
be unaffected by ketamine administration, however impairments are seen in the 
manipulation of information in working memory (Morgan & Curran, 2006). 
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A more recent study indicated that as the difficulty of a visual working memory 
task increased, performance of healthy participants who were administered sub-
anaesthetic ketamine decreased compared to placebo (Koychev, Deakin, El-Deredy, & 
Haenschel, 2017). Healthy participants experiencing induced heat pain and administered 
an acute dose of ketamine (s-ketamine, 0.29mg/kg/hr), were impaired in memory, 
psychomotor speed, complex attention, and the executive function of cognitive 
flexibility, as well as in reaction time as compared to their placebo counterparts 
(Olofsen et al, 2012). Healthy participants given increasing doses of ketamine (8mg/hr; 
12mg/hr; 20 mg/hr) experienced dose dependant effects in complex reaction time, 
visuospatial working memory and spatial planning, but not on simple reaction time 
(Hayley et al, 2017).  
One study with participants receiving ketamine for medical and psychiatric 
problems found those with suicidality and treatment resistant depression (TRD) 
experienced improvements in visual memory, simple working memory, and complex 
working memory (Lee et al, 2016). However, these changes were reported alongside a 
simultaneous reduction in depression (Lee et al, 2016). Research exploring the cognitive 
effects of ketamine for post-surgical pain have found various cognitive effects. Reeves 
et al (2001) found that participants receiving IV ketamine were impaired in 
psychomotor agility when switching as compared to participants receiving IV morphine. 
Two studies showed working memory, attention and switching were not affected when 
participants received either IV ketamine or morphine (Aubrun et al, 2008; Zohar, 2002). 
Unfortunately, there is little research on the cognitive effects of ketamine on 
participants receiving acute sub anaesthetic ketamine for chronic pain. 
Cognitive function and pain. According to a narrative review of chronic pain 
and cognition, persons living with chronic pain often experience a disruption of their 
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cognitive functioning, especially as regards attention, speed of processing information, 
and executive functioning (Baker, Georgiou-Karistianis, Gibson & Giummarra, 2016). 
These authors suggest that the effects of pain on cognition may occur due to several 
mechanisms. They posit that the capacity needed to process pain signals may disrupt 
other cognitive processes - that is, the inherent biological need to pay attention to pain 
signals results in poor attention to other stimuli. They also state that due to the plasticity 
of the human brain, patients experiencing chronic pain may over time have a reduction 
in the volume of their prefrontal cortex and a corresponding increase in amygdala 
function, leading to decreased cognitive control. The authors also note that persons 
experiencing chronic pain are more likely to be tired, to be taking medications which 
may disrupt cognitive functioning, and to have disturbances in mood, all of which 
influence cognitive functioning (Baker et al, 2016). 
In their 2011 review of chronic pain and cognition, Moriarty and colleagues 
explore the specific cognitive consequences of chronic pain. They found that patient 
self-report measures and empirical studies indicate that attention appears to decrease 
with increasing pain, and that the speed at which persons experiencing chronic pain 
process information is slower than controls, especially in tasks which require 
psychomotor ability and perceptual learning ability. The review indicated that tasks of 
executive functioning, especially those which require attention switching or high levels 
of interference, are affected by chronic pain more so than more automatic and less 
complicated or complex tasks (Moriarty, McGuire & Finn, 2011). Finally, the reviewers 
indicated that while the capacity and recall of working, or explicit, memory, verbal 
memory and spatial memory is negatively affected by pain, there is little difference in 
implicit memory performance between chronic pain patients and controls. The 
reviewers do note however that the exact cognitive consequences of chronic pain are 
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difficult to discover, as chronic pain is frequently comorbid with stress, mood disorders 
and fatigue (Moriarty, McGuire & Finn, 2011) 
2.24 Side Effects of Ketamine 
In their review of ketamine for pain, Neisters, Martini and Dahan (2013) indicate 
that hallucinations, urological symptoms, somnolence, dizziness, memory deficits, and a 
feeling of being high appear to be common side-effects of recreational ketamine use. 
Due to this, the authors argue that ketamine should only be used for patients with severe 
and treatment resistant neuropathic pain until further studies are carried out (Neisters, 
Martini & Dahan, 2013). In addition, Visser and Schug (2006) indicate that acute sub-
anaesthetic doses of IV ketamine can cause side effects such as sedation and dizziness. 
However, a study by Cvrcek (2008) indicated that while almost half of participants 
treated with acute sub-anaesthetic ketamine experienced dizziness after infusion, no 
participants experienced memory deterioration or hallucinations, and only one 
experienced nausea and vomiting.  
2.25 Lidocaine 
Lidocaine, also known as lignocaine, is widely used non-opioid anaesthetic drug 
which works in nerves by blocking sodium channels and interrupting transmission 
(Eipe, Gupta & Penning, 2016). 
Lidocaine and pain. Acute intravenous lidocaine is regularly used in the 
management of neuropathic pain and may be an effective treatment for reducing severe 
chronic pain (Carroll, Gaeta & Mackey, 2007). A randomised double-blind study 
indicated that an infusion of lidocaine was beneficial for participants with diabetic 
neuropathy at one and eight days after infusion, and that the effect of the drug lasted up 
to 21 days for some participants (Kastrup, Petersen, Dejgård, Angelo, & Hilsted, 1987). 
A more recent review of the literature by Souza and Kraychete (2014) indicated that 
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intravenous lidocaine appears to have an analgesic effect in patients with chronic pain, 
but that the duration of this pain relief is variable. 
Lidocaine and cognitive function. In animal models, injections of lidocaine do 
not appear to negatively affect social memory, and may indeed be neuroprotective 
(Mitchell & Merry, 2009; Noack, Murau & Englemann, 2015). Lidocaine appears to be 
neuro-protective when administered to participants undergoing cardiac surgery, and 
there is little evidence that the drug causes specific cognitive deficits (Mitchell & 
Merry, 2009). 
Side effects of lidocaine. Side effects of lidocaine may include, sedation, 
sleepiness, a metallic taste, numbness of the tongue, light-headedness, relaxation, 
euphoria and feeling unreal or feeling intoxicated (Eipe et al, 2016; Kosharskyy, 
Almonte, Shaparin, Pappagallo & Smith, 2013). As concentrations of lidocaine reach a 
toxic level, visual disturbances, muscle twitching and seizures may develop, along with 
unconsciousness, coma, respiratory arrest and cardiovascular collapse (Eipe et al, 2016; 
Kosharskyy et al, 2013). 
2.26 Rationale for Current Study 
Cognitive function can be affected by pain, mood, and analgesic drugs. The 
relationship between the three factors appears to be as illustrated in Figure 2.1. 
 
Figure 2.1: The relationship between cognition, pain and mood  
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The study aims to investigate the effects of ketamine on cognitive functioning 
and chronic pain, and to describe the relationships between cognitive functioning and 
acute pain relief in patients receiving acute sub-anaesthetic intravenous ketamine, and 
those receiving acute lidocaine as part of their routine treatment for chronic pain. 
This was a joint project, and the partner project focuses on exploring the 
relationship between pain and mood.  
2.3 Method 
2.31 Ethics 
Ethical approval for this study, Integrated Research Application System Number 
214864, was granted by the South Central - Berkshire Research Ethics Committee (see 
Appendix 2.A). No modifications were made to participants’ routine medical care, and 
all participants were required to give informed consent before taking part. Information 
about the study was provided to participants at least 24 hours before they were 
scheduled to participate (See Appendix 2.A and 2.B for information sheets and consent 
forms used). Participants were assured that involvement was voluntary, that they could 
withdraw from the study at any time, and that not participating in the study would not 
affect their treatment or care in any way. All participants provided informed consent. 
2.32 Setting & Participants 
The study site is a nationally recognised centre of excellence for people with 
chronic pain, which serves both the local and national population. The team is 
multidisciplinary, and pain is viewed through medical, psychological and social lenses. 
Along with infusions of ketamine and lidocaine, the service also provides other 
specialist interventions such as systemic drug treatment, intravenous drug infusions, 
peripheral and central nerve blocks, radio frequency lesioning and spinal implants, 
psychological support, access to TENS machines and acupuncture. 
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Lidocaine is typically used as the first line of treatment for infusion patients at 
the clinic. However, those patients with a history of heart disease or those who are 
deemed to be at high risk for cardiac complications will be prescribed ketamine. 
Patients without cardiac complications will be prescribed ketamine only if they show no 
or limited response to lidocaine.  
Participants were patients receiving specialist pain management in the UK, and 
all participants were receiving either ketamine or lidocaine as part of their routine 
medical treatment for chronic pain. In order to be considered for inclusion in the study, 
potential participants were required to: 
- Be receiving ketamine or lidocaine IV infusions for moderate or severe chronic 
neuropathic pain 
- Be between the ages of 18 and 70 
- Be native or fluent English speakers 
- Have normal or corrected to normal vision 
- Have normal or corrected to normal hearing 
- Have no record of serious head injury 
- Have no record of learning difficulties 
- Be willing and able to provide informed consent  
Potential participants were excluded if they had been diagnosed with a psychiatric 
illness, were pregnant or breastfeeding, or were unable to provide informed consent. 
The researchers aimed to recruit 24 participants for each treatment condition; a 
total of 48 participants. As this study was exploratory in nature, intended sample size 
was determined by discussions of feasibility with a Consultant in Pain Medicine and 
Anaesthesia, and by a historical review of numbers of infusions occurring at the study 
site. 
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Attempts were made to contact all patients due to receive a ketamine or 
lidocaine infusion between the beginning of February 2018 and end May 2018. 
Participants were 58 adults between the ages of 20 and 70. 24 participants, seven male 
and 17 female were receiving ketamine, and 34 participants were receiving lidocaine, 
seven male and 27 female. Characteristics of participants are described in Table 2.2 in 
the results section 
2.33 Research Design 
This study used a non-randomised, between subjects, active control design. As 
the independent variable of drug (ketamine or the control lidocaine) was a part of 
participants’ regular medical treatment, it was not possible to blind participants. In 
addition, as infusion length was significantly different between the two drug groups, 
with ketamine infusions lasting from 30 minutes to one hour, and lidocaine infusions 
lasting from one hour to two hours, it was not possible to blind researchers.  
2.34 Measures 
Along with demographic details, three measures of pain and three measures of 
cognition were included (See Appendix 2.C for pain and cognitive measures given to 
participants). The decision to use the specific tasks outlined below was made in 
consultation with clinic staff and through piloting.  
Pain visual analogue scales. Participants indicated their current state on three 
0-10 Visual Analogue Scales (VAS) related to aspects of pain as follows: Pain Intensity 
(0 – no pain, to 10 – extremely intense pain); Pain Distress (0 – no distress, to 10 – 
extremely distressing); Pain Interference (0 – does not interfere, to 10 – interferes with 
everything). 
Story recall. Immediate and delayed episodic memory was tested using two 
stories from the Story Recall subtest of the Rivermead Behavioural Memory Test (SR-
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RBMT – Wilson, Cockburn & Baddeley, 1985). The Story Recall subtest involves 
measures of delayed and immediate recall. In the immediate recall condition, the 
participant was asked to listen to a short passage of prose being read aloud, immediately 
after which they were asked to recall as much of the passage as they remembered. In the 
delayed recall condition, the participant was asked to recall as much as they could of the 
passage they heard earlier (See Appendix 2.D for an overview of the scoring guidelines 
used for the story recall tasks) 
Serial sevens. The Serial Sevens Subtraction task is a task of working memory 
and attention. Participants were given a number and asked to subtract seven from that 
number. They were then asked to subtract seven from the resulting number and to 
continue subtracting seven over a period of 60 seconds.  
Verbal fluency (H & L). The verbal fluency task measures the production of 
words beginning with the same letter within a timed period. Participants were given a 
letter of the alphabet and asked to produce as many words as possible (excluding proper 
nouns) starting with that letter in 60 seconds. Proper nouns, words did not start with the 
target letter or repetitions were scored as errors.  
2.35 Procedure 
The direct care team at the site identified possible study participants. 
Participants thus identified were contacted by researchers to determine eligibility. Upon 
arrival at their appointment, participants provided informed consent and their 
demographic details (gender, age and highest level of education). 
Pre-infusion baseline. Participants first completed the three pain VAS, and then 
the cognitive tasks in the following order: story 1 of the SR-RBMT, immediate recall 
condition; a verbal fluency task; a serial sevens subtraction task. The latter tasks were 
counterbalanced across participants.  
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Infusion. Prior to infusion, physiological instruments to monitor vital signs 
(heart rate, systolic/diastolic blood pressure, respiratory rate and oxygen saturation) 
were attached and participants cannulated. Ketamine infusions lasted 30-60 min, 
however one participant received a two-hour ketamine infusion. Most lidocaine 
infusions lasted between one and two hours. Protocols for treatment dose were 
0.5mg/kg for ketamine participants and 2 or 3mg/kg for lidocaine participants. Infusion 
start time was noted and intended length of infusion was reported to the researchers by 
the clinical staff. 
Mid-infusion. Infusion mid-point was determined for each participant based on 
anticipated infusion duration, and at this time the three pain VAS were repeated. 
Participants then were asked to complete story 2 of the SR-RBMT, immediate recall 
condition, another verbal fluency task and a serial sevens task (again, these tasks were 
counterbalanced across participants). Finally, participants completed story 1 of the SR-
RBMT, delayed recall condition, and story 2 of the SR-RBMT, delayed recall 
condition. 
Post infusion. Immediately post-infusion, participants were debriefed by 
researchers and given the opportunity to ask questions. Participants stayed in the clinic 
post infusion and were monitored until cleared to leave by the clinical team. An 
overview of task timing during the study is given below in Table 2.1. 
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Table 2.1 
Timing of task administration 
Prior to Infusion (Time 1) Infusion Begins Mid Infusion (Time 2) 
Visual Analog Sale - Visual Analog Sale 
- Pain Intensity - - Pain Intensity 
- Pain Distress - - Pain Distress 
- Pain Interference - - Pain Interference 
Story 1 - Story 2 
- Immediate Recall - - Immediate Recall 
Verbal Fluency  - Verbal Fluency 
Serial Sevens - Serial Sevens 
 - Story 1 
 - - Delayed Recall 
 - Story 2 
 - - Delayed Recall 
 
2.36 Statistical Analysis 
Variables related to pain and cognitive functioning were evaluated for normality 
of distribution, using the Shapiro-Wilk Test, a preferable test of normality due to its 
power, (Ghasemi & Zahediasl, 2012; Mohd Razali & Yap, 2011). Missing variables 
were excluded pairwise (See Appendix 2.E for the results of the Shapiro-Wilk tests of 
normality for baseline and midpoint pain and cognition scores). In the Shapiro-Wilk 
test, a significant value indicates a deviation from normal, and according to results 
much of the data did not appear to be normally distributed. It is important to note that 
while statistical tests of normality are useful, they can be prone to error, so plots of the 
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data were visually examined for normality – that is, histograms were created which 
were then compared to a normal bell curve. Quartile-quartile plots of the data indicated 
that the data appeared to be linear, however histograms of the data showed the effects of 
skew and kurtosis. 
  There is no easily accessible non-parametric variation of a mixed ANOVA. 
According to Field (2018) however, the F-test in ANOVA is a robust measure – that is, 
it can tolerate violations of its assumption of normality. In addition, Field noted that in 
samples of 40 or more, the sampling distribution is usually normal, and recommended 
that where possible it is preferable to use a robust measure such as the F-test, especially 
if the data is linear but affected by skew or kurtosis (Field, 2018). Thus, in order to 
explore the interactions between drug and time, the main effects of drug, and main 
effects of time on the domains of pain and cognition, mixed ANOVAs were used.  
Nonetheless, to confirm results of these parametric analyses, non-parametric 
Mann-Whitney tests were used to determine if change scores for pain and cognition 
were significantly different in the lidocaine and ketamine groups.  
Secondary data analysis involved exploring the ways in which variables were 
associated. Correlations were run to determine if there was covariance in the ways in 
which the domains of pain and the domains of cognitive functioning changed over time. 
As tests of normality on change scores appeared to be non-parametric, and histograms 
of the data did not appear to follow the normal bell curve, the Spearman's rho 
correlation coefficient was used (See Appendix 2.F for Shapiro-Wilk tests of normality 
for pain and cognition change scores). 
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2.4 Results 
2.41. Demographics 
58 participants completed the study, 34 in the lidocaine group and 24 in the 
ketamine group. Demographic details collected included participant age, sex and highest 
educational level. Participants in each group were statistically similar, and the 
characteristics of the study sample are given in Table 2.2. Age and gender distributions 
for the total study population, including those of the population who were included in 
the study sample are given in Table 2.3.  
Table 2.2. 
Characteristics of study sample and results of the statistical differences between groups 
Characteristic Lidocaine Ketamine Statistical Tests 
N 34 24  
Age:  
Mean ± SD  
(range) 
 
48.03±13.76  
(20-69) 
 
51.75±13.19  
(24-70) 
t(56)=1.032, p=0.307 
 
 
Sex:   X2(1) =0.565, 
p=0.328 
Male 7 (20.6%) 7 (29.2%)  
Female 27 (79.4%) 17 (70.8%)  
Education level (years)*: 13.31 13.36 t(52)=0.011, p=0.991 
Dose of drug (mg) 195.80 
(61.68) 
20.52 (12.59)  
*. Data missing for four participants, two lidocaine and two ketamine 
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Table 2.3. 
Age and gender distributions for the total study population 
    Ketamine Lidocaine 
Age    N Mean ± SD N Mean ± SD 
  1Study Population 24 51.75± 3.19 34 48.03±13.76 
  2Full Population 74 55.77±12.18 188 50.20±14.14 
Gender (Female)   N (%) N (%) 
  1Study Population 17 (70.8%) 27 (79.4%) 
  2Full Population 46 (62.2%) 137 (72.9) 
1Study Population: All participants who participated in the study  
2 Full Population: all patients attending the study site for infusions between February 
and May 2018, including the study population 
In all statistical tests used, Time 1 was defined as tasks completed prior to 
infusion, while Time 2 was defined as tasks completed at the mid-point of the infusion.  
2.42. Pain 
Change in pain was analysed using mixed ANOVAs, the full results of which 
are reported in Table 2.4. 
Results indicated a significant interaction between time and drug (see figure 
2.2), no main effect of drug, and a main effect of time on pain intensity.  
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Table 2.4. 
Results of mixed ANOVA exploring the effects of drug and time on pain 
Pain Domain  Time 1 Means: 
Lidocaine (SD) 
Ketamine (SD) 
Time 2 Means: 
Lidocaine (SD) 
Ketamine (SD)  
ANOVA 
Conditions 
F(1,55) Sig. 
(p) 
Pain Intensity 6.58 (2.09) 
7.15 (1.98) 
4.98 (2.10) 
3.33 (2.22) 
Drug x time 15.74 .0001* 
   Drug 1.22 .274 
   Time 93.11 .0001* 
Pain Distress 5.82 (2.70) 
5.96 (2.90) 
3.32 (2.47) 
2.31 (2.57) 
Drug x time 2.78 .101 
   Drug .48 .490 
   Time  79.91 .0001* 
Pain 
Interference 
7.16 (2.90) 
7.41 (2.52) 
3.75 (3.40) 
1.91 (2.27) 
Drug x time 4.97a .030* 
   Drug  1.57a .213 
   Time  89.84a .0001* 
*. Indicates significance at the 0.05 level  a. Indicates F(1,53) 
 
 
Figure 2.2: Measure of Pain Intensity Before and After Drug Administration for 
Participants Administered Ketamine and Lidocaine 
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There was no significant effect of time and drug on pain distress, and no main 
effect of drug. There was however a significant reduction in pain-related distress after 
drug administration. Pain interference showed an interaction between time and drug 
(See figure 2.3). There was no main effect of drug, but there was a significant effect of 
time 
 
Figure 2.3: Measure of Pain Interference Before and After Drug Administration for 
Participants Administered Ketamine and Lidocaine 
As the data appeared non-parametric, the more conservative Mann-Whitney tests 
were used to confirm findings. Change scores were computed in SPSS by taking the 
baseline value from the midpoint value for each variable. Results of these tests are 
shown in Table 2.5. Ketamine participants experienced a significantly larger decrease in 
pain intensity after drug administration than lidocaine patients. This group of 
participants also displayed a significantly larger decrease in pain interference as 
compared to their lidocaine counterparts. There was no significant difference found 
between the groups on the domain of pain distress, indicating that the significant 
ANOVA results for pain distress should be treated with caution. 
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Table 2.5. 
Mann-Whitley tests on change scores of pain  
 Median 
Ketamine 
(N) 
Median 
Lidocaine 
(N) 
U Z P R 
Pain Intensity 0 (24) 1 (33) 614.00 3.56 0.001* 0.47 
Pain Distress 0 (24) 1 (33) 502.50 1.74 0.082 0.23 
Pain Interference 1 (23) 2 (32) 488.50 2.07 0.038* 0.27 
*. Indicates a significant difference at the 0.05 level 
2.43. Cognition 
Change in cognitive functioning was analysed using mixed ANOVAs, the full 
results of which are reported in Table 2.6.  
Verbal fluency. There were significant main effects of drug and time on correct 
responses during the verbal fluency task, but no interaction between time and drug. The 
lidocaine group produced more correct responses than the ketamine group at both T1 
and T2; the main effect of time reflected more correct responses overall at T2 than T1.   
There was no significant interaction between drug and time on the total number of 
errors made during the verbal fluency task, no main effect of drug, and no main effect of 
time.  
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Table 2.6. 
Group means (SD) pre-drug (T1) and post-drug (T2) and results of mixed ANOVAs 
exploring the effects of drug and time on cognitive tasks 
Cognitive 
Domain  
Time 1 
Means: 
Lidocaine 
(SD) 
Ketamine 
(SD) 
Time 2 
Means: 
Lidocaine 
(SD) 
Ketamine 
(SD)  
ANOVA 
Conditions 
F(1,55) Sig. (p) 
Verbal 
Fluency N 
Correct 
11.24 (5.05) 
10.67 (4.16) 
13.76 (5.90) 
11.25 (4.52) 
Drug x Time 2.214 0.142 
   Drug 6.906 0.011* 
   Time 5.696 0.020* 
Verbal 
Fluency Total 
Errors 
0.55 (0.75) 
1.04 (1.23) 
0.64 (0.96) 
0.79 (1.02) 
Drug x Time 0.995 0.323 
   Drug 2.611 0.112 
   Time 0.217 0.643 
Serial Sevens 8.12 (7.10) 
8.42 (6.78) 
8.61 (6.14) 
5.79 (4.85) 
Drug x 
Time 
9.830 0.003* 
   Drug 0.600 0.442 
   Time 4.655 0.035* 
Story 1 Recall 4.89 (2.62) 
5.07 (3.18) 
2.58 (2.13) 
2.50 (2.75) 
Time x Drug 0.296a 0.589 
   Drug 0.007a 0.935 
   Time 101.961a 0.0001* 
Story 2 Recall 6.50 (2.34) 
5.22 (3.53) 
4.98 (2.37) 
3.46 (3.58) 
Time x Drug 0.183a 0.671 
   Drug 3.666a 0.061 
   Time 32.502a 0.0001* 
Immediate 
Story Recall 
4.88 (2.62)  
5.04 (3.12) 
6.50 (2.34) 
5.06 (3.53) 
Drug x time 4.836 0.032* 
   Drug .885 0.351 
   Time 5.091 0.028* 
Delayed Story 
Recall 
2.58 (2.13) 
2.50 (2.75) 
4.98 (2.37) 
3.46 (3.58) 
Drug x 
Time 
5.368 0.024* 
   Drug 1.496 0.227 
   Time 28.818 0.0001* 
*. Indicates significance at the 0.05 level 
a. Indicates F(1,53) 
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Serial Sevens. There was a significant interaction of drug and time and a 
significant main effect of time (see figure 2.4), but no main effect of drug.  
 
Figure 2.4: Changes in Serial Sevens Performance Before and After Drug 
Administration for Participants Administered Ketamine and Lidocaine 
Story Recall. Results indicated a main effect of time on the recall of story 1, 
where both groups showed a significant decline in recall. However, there was no 
interaction of time and drug, and no main effect of drug. The ability to recall story 2 
was significantly affected by time, but again there was no significant interaction 
between time and drug, and no significant main effect of drug. 
For the immediate recall of a story pre-drug (T1)  and post-drug (T2) there was a 
significant main effect of time, and a significant interaction between time and drug (see 
figure 2.5), but no significant main effect of drug. For the delayed recall of a story post 
drug administration, there was a significant interaction of time and drug (see figure 2.6), 
and a significant main effect of time, but no significant main effect of drug 
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Figure 2.5: Immediate Recall for Information Learned and Recalled at Baseline 
compared to Information Learned and Recalled After Drug Administration for 
Participants Administered Ketamine and Lidocaine  
 
Figure 2.6: Delayed Recall of Information Learned at Baseline and Recalled Post Drug 
Administration, as compared to Delayed Recall of Information both Learned and 
Recalled Post Drug for Participants Administered Ketamine and Lidocaine 
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As with the data for pain, the cognitive data appeared to violate assumptions 
required for parametric analysis/ Change scores were analysed using Mann-Whitney 
tests and results were largely in line with results from the ANOVA’s (see Table 2.7). 
Results of Mann-Whitney tests indicated that ketamine participants had a significant 
change in their post drug performance on the serial sevens task as compared to the 
lidocaine group. In a task of immediate recall of a story, participants receiving ketamine 
were significantly more impaired than lidocaine participants after drug administration. 
Ketamine participants were also significantly more impaired on a task requiring the 
delayed recall of a story than their lidocaine counterparts. No other cognitive tasks 
showed a significant difference in the Mann-Whitney results. 
Table 2.7 
Mann-Whitley tests on change scores of cognition 
 Median 
ketamine (N) 
Median 
lidocaine (N) 
U Z P r 
Fluency correct -0.50 (24) -2.00 (33) 463.50 1.095 0.274 0.14 
Fluency total 
errors 
0.00 (24) 0.00 (34) 453.00 0.963 0.336  
Serial sevens 2.00 (24) -1.00 (33) 594.00 3.223 0.001* 0.43 
Immediate 
recall 
-1.00 (24) -1.5 (33) 572.00 2.853 0.004* 0.378 
Delayed recall 0.50 (23) 2.00 (33) 541.00 2.250 0.024* 0.301 
*. Indicates a significant difference at the 0.05 level 
2.44. Secondary Analysis – Correlations 
Table 2.8 shows the means, standard deviation and Spearman’s Rho correlations 
between changes in pain and cognitive domains by drug administered.  
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Lidocaine. In lidocaine participants, change in pain intensity was significantly 
positively correlated with change in pain distress, pain intensity was significantly 
positively correlated with pain interference, and pain distress was significantly 
positively correlated with change in pain interference. Change in pain distress was 
significantly negatively correlated with a change in the amount of errors on a task of 
verbal fluency. 
Errors in verbal fluency were significantly negatively correlated with the 
immediate and delayed recall of story 1. The immediate and delayed recall of story 1 
was significantly positively correlated with overall immediate recall, as was the 
immediate and delayed recall of Story 2 with overall immediate recall. Overall 
immediate recall was significantly positively correlated with overall delayed recall. 
Ketamine. In ketamine participants, change in pain intensity was significantly 
positively correlated with change in pain distress, and pain intensity was significantly 
positively correlated with pain interference, however there was no significant 
relationship between pain distress and pain interference. Change in pain distress was 
significantly negatively correlated with performance on the immediate and delayed 
recall of story 1. Change in pain interference was significantly positively correlated with 
measures of delayed recall.  
Changes in number of correct responses on a task of verbal fluency were 
significantly negatively correlated with errors on that same task. Immediate and delayed 
recall of story 1 was significantly positively correlated with overall immediate recall. 
However, the immediate and delayed recall of Story 2 was significantly negatively 
correlated with overall immediate recall. 
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Table 2.8. 
Means, standard deviation and Spearman’s rho correlations between changes in pain and cognitive domains 
Drug Measure Mean  SD N 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 
Lidocaine  1. Pain Intensity 1.59 1.74 33 - 0.41* 0.44* -0.17 -0.12 -0.15 0.12 -0.04 0.17 0.062 
 2. Pain Distress 2.50 2.31 33 0.41* - 0.58** -0.03 -0.45** -0.24 0.02 0.12 -0.13 -0.01 
 3. Pain Interference 3.41 3.58 32 0.44* 0.58** - -0.04 -0.20 -0.07 -0.18 -0.02 0.06 0.27 
 4. Verbal Fluency Correct -2.51 4.99 33 -0.17 -0.03 -0.04 - 0.10 0.17 -0.19 -0.13 -0.18 -0.30 
 5. Verbal Fluency Total Errors -0.09 0.80 33 -0.12 -0.45** -0.20 0.10 - 0.33 -.35* -0.05 -0.12 -0.02 
 6. Serial Sevens -0.48 2.96 33 -0.15 -0.23 -0.07 0.17 0.33 - 0.07 -0.01 -0.01 -0.13 
 7. Story 1 Recall 2.30 1.55 33 0.12 0.02 -0.18 -0.19 -0.35* 0.07 - 0.18 0.40* -0.14 
 8. Story 2 Recall 1.52 1.90 33 -0.04 0.12 -0.02 -0.13 -0.05 -0.01 0.18 - -0.52** 0.09 
 9. Story Immediate Recall -1.62 2.40 33 0.17 -0.13 0.06 -0.18 -0.12 -0.01 0.40* -0.52** - 0.49** 
 10. Story Delayed Recall -2.41 1.82 33 0.06 -0.01 0.27 -0.30 -0.02 -0.13 -0.14 0.09 0.49** - 
Ketamine 1. Pain Intensity 3.81 2.49 24 - 0.72** 0.47* 0.14 0.18 0.12 -0.04 -0.27 0.13 0.18 
 2. Pain Distress 3.65 2.88 24 0.72** - 0.41 0.35 0.15 0.09 -0.05 -0.43* 0.02 -0.01 
 3. Pain Interference 5.50 3.22 23 0.47* 0.41 - 0.20 0.10 0.20 -0.40 0.06 -0.22 0.43* 
 4. Verbal Fluency Correct -0.58 4.61 24 0.14 0.35 0.20 - -0.45* 0.29 0.09 -0.12 -0.09 -0.04 
 5. Verbal Fluency Total Errors 0.25 1.73 24 0.18 0.15 0.10 -0.45* - 0.04 -0.25 -0.02 0.13 0.07 
 6. Serial Sevens 2.63 4.53 24 0.12 0.09 0.20 0.29 0.04 - 0.17 -0.17 0.33 0.16 
 7. Story 1 Recall 2.57 2.06 23 -0.04 -0.05 -.40 0.09 -0.25 0.17 - 0.11 0.46* -0.37 
 8. Story 2 Recall 1.76 2.40 23 -0.27 -0.43* 0.06 -0.12 -0.02 -0.17 0.11 - -0.45* 0.21 
 9. Story Immediate Recall -0.02 3.10 24 0.13 0.02 -.22 -0.09 0.13 0.33 0.46* -0.45* - 0.19 
 10. Story Delayed Recall -0.96 2.87 23 0.18 -0.01 0.43* -0.04 0.07 0.16 -0.37 0.21 0.19 - 
* Correlation is significant at the 0.05 level (2-tailed) 
** Correlation is significant at the 0.01 level (2-tailed) 
   
93 
 
2.5 Discussion  
This paper described a non-randomised between subjects study of the effects of 
sub-anaesthetic IV infusions of ketamine compared to those receiving IV infusions of 
lidocaine on the cognitive functioning in participants receiving the drugs for chronic 
pain. The study compared the two groups in terms of changes in pain, episodic memory, 
working memory and attention, and verbal fluency.  
2.51 Summary & Interpretation of Results 
Pain. Administration of ketamine significantly reduced participant levels of pain 
intensity, pain distress and pain interference. Indeed, ketamine was significantly more 
effective than lidocaine in acutely reducing pain intensity and pain interference, but not 
in reducing pain distress. The three domains of pain appeared to be related in both 
groups of participants.  
These results are in line with previous research which reported that acute sub-
anaesthetic ketamine leads to pain reduction in patients with chronic cancer pain and for 
patients with chronic neuropathic pain (Bell et al, 2017; Visser & Schug, 2006). 
Some of the various biological and evolutionary factors that may contribute to 
cognitive disruption in persons with chronic pain have been outlined in the introduction. 
However it is important to again note that chronic pain itself can lead to reduced 
attention, decreased processing speed and decreased executive functioning (Baker et al, 
2016; Moriarty et al, 2011) as well as to a reduction in the capacity and recall of 
working, or explicit memory, verbal memory and spatial memory (Moriarty et al, 2011). 
It follows therefore that some of the increased cognitive ability observed in participants 
in this study may be related to the corresponding decrease in the three pain domains. 
Phonological fluency. Both groups of participants significantly increased in 
phonological fluency performance post drug administration, probably reflecting a 
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practice effect. Previous research on healthy volunteers indicated that simple 
phonological fluency does not appear to be impaired by ketamine (Fu el at, 2005). 
However, a study of chronic somatoform pain disorder patients indicated that pain 
patients were impaired in a task of verbal fluency as compared to healthy controls (Ren 
et al, 2017). 
Working memory & attention. The ketamine group was significantly impaired 
post-drug on a task of working memory and attention as compared to the lidocaine 
group. While the lidocaine group of participants experienced a small increase in 
performance on this task post drug, the ketamine group of participants experienced an 
impairment in their post drug functioning.  
Simple attention and the maintenance of information in working memory 
appeared to be unaffected by ketamine (Aubrun et al, 2008; Morgan & Curran, 2006; 
Zohar et al, 2002). However, the serial sevens task used involves the manipulation of 
information in working memory. More difficult tasks, and tasks which involve 
manipulation of working memory have been shown to be impaired by ketamine (Honey 
et al, 2003; Koychev et al, 2017; Morgan & Curran, 2006). Finally, as reported 
previously, chronic pain can impair working memory and attention, so the slight 
increase in ability of the lidocaine group may have been related to the decrease in pain.  
Episodic memory. Participants in both the ketamine and lidocaine groups 
performed significantly better in the immediate recall of episodic memory than they did 
in the delayed recall of episodic memory.  
Participants administered lidocaine performed significantly better on a task of 
immediate recall after drug administration than they did on this task before drug 
administration, whereas there was no significant change in immediate recall in the 
ketamine group after drug administration.  
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Delayed Recall – both ketamine and lidocaine groups performed better on the 
delayed recall of a story presented before drug administration than they did on the 
delayed recall of a story presented before drug administration. However, the lidocaine 
group exhibited significantly greater delayed recall for information presented after drug 
administration then the ketamine group. 
Pain has been reported to impair memory (Moriarty et al, 2011), and the findings 
from this study imply that a reduction in pain may have led to increased memory 
functioning. However, while both groups experienced increased memory ability in the 
delayed recall of information, the lidocaine groups were significantly more improved 
than the ketamine groups in both the delayed recall and the immediate recall of 
information learned after drug administration. 
Previous studies indicate that ketamine does not impair episodic memory for 
information learned before drug administration (Morgan & Curran, 2006; Morgan, 
Mofeez, Brandner, Bromley & Curran, 2004a). However, research indicates that 
ketamine does impair episodic memory for information learned under the influence of 
the drug. (Morgan & Curran, 2006; Morgan et al, 2004a).  
Pain and cognition. For participants administered lidocaine, decreased pain 
distress was related to reduced incidence of errors on a measure of phonological 
fluency. In ketamine participants, as pain distress decreased, the post-drug ability to 
recall episodic information learned before drug administration increased. In addition, a 
change in pain interference was positively correlated with delayed recall of episodic 
memory.  
Ketamine participants also experienced a decrease in their verbal fluency 
correlated with an increase in their errors on that task. Finally, in ketamine participants, 
the immediate and delayed recall of the story learned pre drug was positively correlated 
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with overall immediate recall, however, the immediate and delayed recall episodic 
information learned post drug was significantly negatively correlated with overall 
immediate recall. 
2.52 Limitations 
 As this study was with patients receiving ketamine and lidocaine as part of their 
routine medical care, it was not possible to control drug doses, or to blind participants or 
medical staff to drug group. In addition, due to the variation in length of drug infusions, 
it was not possible to blind researchers to drug group. 
A further limitation regarding infusion length relates to time elapsed between 
pre-drug and post-drug cognitive tests. Ketamine infusions were between 30 and 60 
minutes long, with one outlier receiving a two-hour infusion, while lidocaine infusions 
lasted between one and two hours. Due to this, ketamine participants repeated cognitive 
measures after 20-40 minutes, while lidocaine participants repeated cognitive measures 
after 30-60 minutes. It is possible that ketamine participants may have had an advantage 
due to recency effects. However, it is important to note that ketamine participants were 
impaired compared to lidocaine participants on most cognitive tasks.  
Due to the medical setting of the study, while protocols for treatment dose were 
0.5mg/kg for ketamine participants and 2 or 3mg/kg for lidocaine participants, some 
participants received slightly higher or lower doses of drug. In addition, several 
participants were not naïve to these drugs and had received ketamine or lidocaine 
infusions previously. Further complicating matters, several participants in the ketamine 
group had been administered lidocaine in the past, but as they were not responsive to 
this drug they were then prescribed ketamine.  
Other limitations include the physical area in which participants were 
experiencing chronic pain. While initial pain scores were similar between the two 
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groups, the body parts affected varied. In addition, participants had been experiencing 
chronic pain for different lengths of time, they had different levels of physical 
functioning and they were prescribed varying medications for their pain and for any 
other conditions.  
2.53 Implications of the Research 
Chronic pain is a costly burden – for the individual experiencing pain, for their 
families, and for the health and economic systems involved (Dueñas, Ojeda, Salazar, 
Mico, & Failde, 2016; Phillips, 2009). Unmanaged chronic pain can lead to 
absenteeism, reduced productivity and long-term incapacity – however, as many as 40% 
of persons experiencing chronic pain report that their pain is not managed effectively 
(Phillips, 2009).  
Psychological interventions are useful in the management of chronic pain as 
they help patients understand the ramifications of their pain behaviours, to decrease 
unhealthy and increase healthy coping mechanisms, and to understand and modify the 
thought and emotional patterns associated with their chronic pain (Eccleston, 2001; 
Eccleston, Morley, & C. de C. Williams, 2013). More and more research is emerging 
which supports the notion that multidisciplinary pain management is both cost effective 
and effective in the reduction of pain and improvement of overall quality of life (Giusti 
et al, 2017). However, while there is research supporting the efficacy of psychological 
interventions (Cano-García, González-Ortega, Sanduvete-Chaves, Chacón-Moscoso, & 
Moreno-Borrego, 2017; Eccleston, Morley, & C. de C. Williams, 2013) evidence 
surrounding pharmacological interventions for the management of chronic pain is poor.  
There are several pharmacological therapies available for patients with chronic 
neuropathic pain, however research has yet to find a panacea that works for all patients 
with all types of chronic pain (Finnerup, Otto, McQuay, Jensen, & Sindrup, 2005). 
   
98 
 
Indeed, a 2010 review of drug therapy for chronic back pain found only a small effect of 
non-steroid anti-inflammatory drugs and opioids as compared to placebo, and no effect 
of antidepressants, with all three drug categories inducing adverse effects in participants 
(Kuijpers, 2011). Because of this, research on the analgesic properties of ketamine and 
other NMDA receptor antagonists, as well as their cognitive correlates and adverse 
effects is important  
2.54 Conclusions 
Research on the pain relieving properties of NMDA receptor antagonists has 
been ongoing for almost three decades (Childers & Baudy, 2007). However, little is 
known about the cognitive effects of an acute sub-anaesthetic dose of ketamine in 
patients with chronic neuropathic pain. This findings of this study indicated that acute 
ketamine produced more short-term pain relief than lidocaine. Working memory was 
impaired by ketamine administration, as was episodic memory for information learned 
under the influence of the drug. Further research should focus on the longer term pain 
relieving properties of the drug, on comparisons of ketamine’s efficacy to other 
common analgesics, and on the cognitive consequences of long term and repeated 
ketamine administration in persons with chronic pain. 
 
  
   
99 
 
2.6 References 
Cvrcek, P. (2008). Side effects of ketamine in the long-term treatment of neuropathic 
pain. Pain Medicine, 9, 253-257. 
Koychev, I., Deakin, J.F.W., El-Deredy, W. & Haenschel, C. (2017). Effects of acute 
ketamine infusion on visual working memory: Event-related potentials, Biological 
Psychiatry: Cognitive Neuroscience and Neuroimaging, 2, 253-262. 
Lee, Y., Syeda, K., Maruschak, N.A., Cha, D.S., Mansur, R.B., Wium-Andersen, I.K., 
Woldeyohannes, H.O., Rosenblat, J.D., & McIntyre, R.S. (2016). A new 
perspective on the anti-suicide effects with ketamine treatment: A procognitive 
effect. Journal of Clinical Psychopharmacology, 36, 50–56. 
Olofsen, E., Noppers, I., Niesters, M., Kharasch, E., Aarts, L., Sarton, E. & Albert, D. 
(2012). Estimation of the contribution of norketamine to ketamine-induced acute 
pain relief and neurocognitive impairment in healthy volunteers. Anesthesiology, 
117, 353-364 
Hayley, A., Green, M., Downey, L., Keane, M., Kostakis, P., & Shehabi, Y. (2017). 
Acute and residual effects of stepwise increasing therapeutic doses of ketamine on 
neurocognitive and neurobehavioural performance in healthy adults. European 
Neuropsychopharmacology, 27 [Abstract]. 
Reeves, M., Lindholm, D. E., Myles, P.S., Fletcher, H., & Hunt, J.O. (2001). Adding 
ketamine to morphine for patient-controlled analgesia after major abdominal 
surgery: A double-blinded, randomized controlled trial. Anesthesia & Analgesia, 
93, 116–120. 
Aubrun, F., Gaillat, C., Rosenthal, D., Dupuis, M., Mottet, P., Marchetti, F., Coriat, P., 
& Riou, B. (2008). Effect of a low-dose ketamine regimen on pain, mood, 
cognitive function and memory after major gynaecological surgery: A 
   
100 
 
randomized, double-blind, placebo-controlled trial. European Journal of 
Anaesthesiology, 25, 97-105. 
Zohar, E., Luban, I., Zunser, I., Shapiro, A., Jedeikin, R., & Fredman, B.  (2002). 
Patient-controlled bupivacaine wound instillation following cesarean section: the 
lack of efficacy of adjuvant ketamine. Journal of Clinical Anaesthesiology, 14, 
505-511. 
Baker, K.S., Georgiou-Karistianis, N., Gibson, S.J., & Giummarra, M.J. (2016). 
Optimising cognitive function in persons with chronic pain. Clinical Journal of 
Pain (Ahead of Publication) DOI: 10.1097/ajp.0000000000000423  
Bell, R.F., Eccleston, C., & Kalso, E.A. (2017). Ketamine as an adjuvant to opioids for 
cancer pain. Cochrane Database of Systematic Reviews. 
Cano-García, F.J., González-Ortega, M.C., Sanduvete-Chaves, S., Chacón-Moscoso, S., 
& Moreno-Borrego, R. (2017). Evaluation of a psychological intervention for 
patients with chronic pain in primary care. Frontiers in Psychology, 8. 
Carroll, I., Gaeta, R. & Mackey, S. (2007). Multivariate analysis of chronic pain 
patients undergoing lidocaine infusions: Increasing pain severity and advancing 
age predict likelihood of clinically meaningful analgesia. Clinical Journal of Pain, 
23, 702-706. 
Childers, W.E. & Baudy, R.B. (2007). N-methyl-D-aspartate antagonists and 
neuropathic pain: The search for relief. Journal of Medicinal Chemistry, 50, 2257-
2262. 
Dueñas, M., Ojeda, B., Salazar, A. Mico, J.A., & Failde, I. (2016). A review of chronic 
pain impact on patients, their social environment and the health care system. 
Journal of Pain Research, 9, 457-467. 
   
101 
 
Eccleston, C. (2001). Role of psychology in pain management. British Journal of 
Anaesthesia, 87, 144–152. 
Eccleston, C. Morley, S.J. & C. de C. Williams, A. (2013). Psychological approaches to 
chronic pain management: Evidence and challenges. British Journal of 
Anaesthesia, 111, 59–63. 
Eipe, N., Gupta, S., & Penning, J. (2016). Intravenous lidocaine for acute pain: an 
evidence-based clinical update. British Journal of Anaesthesia Education, 16, 
292–298. 
Field, A. P. (2018). Discovering statistics using IBM SPSS statistics. Los Angeles: 
Sage. 
Finnerup, N.B., Otto, M., McQuay, H.J., Jensen, T.S., & Sindrup, S.H. (2005). 
Algorithm for neuropathic pain treatment: An evidence based proposal. Pain, 118, 
289-305. 
Fu, C.H., Abel, K.M., Allin, M.P., Gasston, D., Costafreda, S.G., Suckling, J., Williams, 
S.C., & McGuire, P.K. (2005). Effects of ketamine on prefrontal and striatal 
regions in an overt verbal fluency task: A functional magnetic resonance imaging 
study. Psychopharmacology, 183, 92-102. 
Ghasemi, A., & Zahediasl, S. (2012). Normality tests for statistical analysis: A guide for 
non-statisticians. International Journal of Endocrinology and Metabolism, 10, 
486-489. 
Giusti, E.M., Pietrabissa, G., Manzoni, G.M., Cattivelli, R. Molinari, E., Trompetter, 
H.R., Schreurs, K.M.G., & Castelnuovo, G. (2017). The economic utility of 
clinical psychology in the multidisciplinary management of pain. Frontiers in 
Psychology, 8. 
   
102 
 
Honey, R.A., Turner, D.C., Honey, G.D., Sharar, S.R., Kumaran, D., Pomarol-Clotet, 
E., McKenna, P., Sahakian, B.J., Robbins, T.W. & Fletcher, P.C. (2003). 
Subdissociative dose ketamine produces a deficit in manipulation but not 
maintenance of the contents of working memory. Neuropsychopharmacology, 28, 
2037–2044. 
International Association for the Study of Pain Task Force on Taxonomy (1994). 
Classification of chronic pain: Descriptions of chronic pain syndromes and 
definitions of pain terms. IASP Press, Seattle, Washington. 
Kastrup, J., Petersen, P., Dejgård, A., Angelo, H. R., & Hilsted, J. (1987). Intravenous 
lidocaine infusion — A new treatment of chronic painful diabetic neuropathy? 
Pain, 28, 69-75. doi:10.1016/0304-3959(87)91061-x. 
Kiefer, R.T., Rohr, P., Ploppa, A., Dieterich, H.J., Grothusen, J., Koffler, S., Altemeyer, 
K.H., Unertl, K. & Schwartzman R.J. (2008). Efficacy of ketamine in anesthetic 
dosage for the treatment of refractory complex regional pain syndrome: an open-
label phase II study. Pain Medicine, 9, 1173-201. 
Kim, M., Cho, S. & Lee, J. (2016). The effects of long-term ketamine treatment on 
cognitive function in complex regional pain syndrome: A preliminary study. Pain 
Medicine. 
Kosharskyy, B., Almonte, W., Shaparin, N., Pappagallo, M. & Smith, H. (2013). 
Intravenous infusions in chronic pain management, Pain Physician, 16, 231-249. 
Kuijpers, T., van Middelkoop, M., Rubinstein, S.M., Ostelo, R., Verhagen, A., Koes, 
B.W., & van Tulder, M.W. (2011). A systematic review on the effectiveness of 
pharmacological interventions for chronic non-specific low-back pain. European 
Spine Journal, 20, 40-50. 
   
103 
 
Lawlor, P.G., (2002). The panorama of opioid-related cognitive dysfunction in patients 
with cancer: A critical literature appraisal. Cancer, 94, 1836–1853. 
Mitchell, S.J. & Merry, A.F. (2009). Lignocaine: Neuro-protective or wishful thinking? 
The Journal of Extracorporeal Technology, 41, 37–42. 
Mohd Razali, N. & Yap, B. (2011). Power comparisons of Shapiro-Wilk, Kolmogorov-
Smirnov, Lilliefors and Anderson-Darling tests. Journal of Statistical Modeling 
and Analytics, 2, 21-33. 
Morgan, C.J., & Curran, H.V. (2006). Acute and chronic effects of ketamine upon 
human memory: A review. Psychopharmacology, 188, 408-424. 
Morgan, C. & Curran, V. (2011). Ketamine use: a review. Addiction, 107, 27-38. 
Morgan, C. J., Mofeez, A., Brandner, B., Bromley, L., & Curran, H. V. (2004a). Acute 
effects of ketamine on memory systems and psychotic symptoms in healthy 
volunteers. Neuropsychopharmacology, 29, 208-218.  
Morgan, C., Muetzelfeldt, L. & Curran, V. (2010). Consequences of chronic ketamine 
self-administration upon neurocognitive function and psychological well being. 
Addiction, 105, 121-133. 
Moriarty, O., Mcguire, B. E., & Finn, D. P. (2011). The effect of pain on cognitive 
function: A review of clinical and preclinical research. Progress in Neurobiology, 
93, 385-404. doi:10.1016/j.pneurobio.2011.01.002. 
National Institute for Health and Clinical Excellence (2011). The pharmacological 
management of neuropathic pain in adults in non-specialist settings. NICE 
clinical guidelines. 
Neisters, M., Martini, C. & Dahan, A. (2013). Ketamine for chronic pain: Risks and 
benefits. British Journal of Clinical Pharmacology, 77, 357-367. 
   
104 
 
Noack, J., Murau, R., & Engelmann, M. (2015). Consequences of temporary inhibition 
of the medial amygdala on social recognition memory performance in mice. 
Frontiers in Neuroscience, 9. 
Phillips, C.J. (2009). The Cost and Burden of Chronic Pain. Reviews in Pain, 3, 2-5. 
Ren, X., Lu, J., Liu, X., Shen, C., Zhang, X., Ma, X., Sun, J., Sun, G., Feng, K., Xu, B., 
& Liu, P. (2017). Decreased prefrontal brain activation during verbal fluency task 
in patients with somatoform pain disorder: An exploratory multi-channel near-
infrared spectroscopy study. Progress in Neuro-Psychopharmacology & 
Biological Psychiatry, 1, 153-160. 
Souza, M.F., & Kraychete, D.C. (2014). The analgesic effect of intravenous lidocaine in 
the treatment of chronic pain: a literature review. Revista Brasileira de 
Reumatologia (English Edition), 54, 386-392. doi:10.1016/j.rbre.2014.01.002. 
Subramaniam, K., Subramaniam, B., & Steinbrook, R.A. (2004). Ketamine as adjuvant 
analgesic to opioids: A quantitative and qualitative systematic review. Anesthesia 
& Analgesia, 99, 482-495. doi:10.1213/01.ane.0000118109.12855.07. 
Turk, D.C., Dworkin, R.H., Allen, R.R., Bellamy, N., Brandenburg, N., Carr, D.B., 
Cleeland, C,, Dionne, R., Farrar, J.T., Galer, B.S., Hewitt, D.J., Jadad, A., Katz, 
N.P., Kramer, L.D., Manning, D.C., McCormick, C.G., McDermott, M., McGrath, 
P., Quessy, S., Rappaport, B.A., Robinson, J.P., Royal, M.A., Simon, L., Stauffer, 
J.W., Stein, W., Tollett, J., & Witter, J. (2003). Core outcome domains for chronic 
pain clinical trials: IMMPACT recommendations. Pain, 106, 337–45. 
Visser, E. & Schug, S.A. (2006). The role of ketamine in pain management. Biomedical 
Pharmacotherapy, 60, 341–348. 
World Health Organisation (2016). Fact file on ketamine. Retrieved July 29, 2017, from 
http://www.who.int/medicines/news/20160309_FactFile_Ketamine.pdf?ua=1. 
   
105 
 
Williams, A.C. & Craig, K.D. (2016). Updating the definition of pain. Pain, 157, 2420-
2423. 
Wilson, B.A., Cockburn, J., & Baddeley, A.D. (1985). The Rivermead Behavioural 
Memory Test. London. Pearson Assessment. 
  
   
106 
 
 
 
 
 
 
 
 
 
Part 3: Critical Appraisal 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
107 
 
3.1 Critical Appraisal 
3.11 Gaining Ethical Approval 
The most frustrating aspect of this study was the time consuming process of 
gaining ethical approval. 
The Joint Research Office. The Joint Research Office (JRO) aims to support 
researchers at UCL and UCLH in conforming to the regulatory requirements and safety 
standards set out by the university. The first steps in registering research at UCL involve 
notifying the JRO of intent to submit a data protection application, submitting a data 
protection application, completing a registration form for sponsorship of the study, and 
completing a UCL insurance registration form. 
All of the above documents were submitted between January and February of 
2017. The researchers then spent the next six months chasing a response by sending e-
mails, making telephone contact and turning up physically at the JRO offices. The UCL 
Insurance Registration Form was submitted in February 2017 but confirmation of 
insurance was not given until July 2017. The UCL data protection application was 
submitted in January of 2017, and was granted approval in August of 2017. This six to 
eight month delay was unacceptable, and caused the timeline of the study to be severely 
disrupted as the research could not be submitted for ethical approval until the project 
had JRO approval. The researchers later learned that the department was undergoing 
restructuring, that the employee responsible for the study had left the department, and 
that the study had not been assigned to another JRO employee for several months. 
NHS Ethics. The NHS ethics process itself was considerably more 
straightforward. In order to gain ethical approval for a study on NHS patients, 
researchers must complete a detailed research application using the Integrated Research 
Application System (IRAS), and then upload copies of all study documents such as 
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measures used, consent forms and information forms. The ethics application is then 
booked in, and the IRAS application is submitted online to a Research Ethics 
Committee.  
The IRAS application form for the study was completed and submitted in 
October 2017. In December of 2017, two months after submission, the project received 
ethical approval from the South Central Berkshire Research Ethics Committee. The 
researchers were then able to apply for honorary contracts with the trust in question, and 
to begin piloting in January of 2018.  
Though the submission date for this thesis was June 2018, collection of study 
data began in February 2018 and was not completed until the end of May 2018. 
Fortunately, at the beginning of the study my supervisors recommended starting the 
ethics process very early. If this had not been the case, the quality of the study would 
have been severely compromised. 
3.12 Selecting Appropriate Neurocognitive Tasks 
Measures used in piloting. Five cognitive measures and one measure of pain 
were included in the pilot participant pack. The demands of these tasks were discussed 
with staff at the study site who reported the belief that their patients could complete 
them. These measures are described below: 
Spot-the-word. In order to assess participant’s verbal IQ, the spot-the-word test 
was administered (Baddeley, Emslie, & Nimm-Smith, 1993). During this exercise, 
participants are given a list of paired words, one of which was a real word, the other 
made up. Participants are asked to identify the real word. This test was used to 
determine if the IQ of participants in the lidocaine and ketamine conditions are evenly 
matched. 
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N-back task. The n-back task is used to measure attention and working memory 
at two levels of difficulty (Braver et al, 1997). The task measures attention during the 0-
back condition, where participants were asked to indicate if an image displayed on the 
screen was shown previously. In the easier 1-back condition, participants indicate if the 
image displayed on the screen was shown immediately before, and in the more difficult 
2-back condition, participants determine if the image on screen was the same as the 
image presented two images previously. 
Story recall. Episodic memory was tested using the Story Recall subtest of the 
Rivermead Behavioural Memory Test (Wilson, Cockburn & Baddeley, 1985). The 
Story Recall subtest involves measures of delayed and immediate recall. In the 
immediate recall condition, participants are asked to listen to a short passage of prose 
being read aloud, immediately after which they are asked to recall as much of the 
passage as they remembered. In the delayed recall condition, the participant was asked 
to recall as much as they could of the passage they heard earlier  
Hayling sentence completion. In order to assess response initiation and response 
inhibition, participants completed the Hayling Sentence Completion Task (Burgess & 
Shallice, 1997). In the response initiation condition, participants were read a sentence, 
and asked to finish that sentence with a congruent word. In the response inhibition 
condition, participants were read a sentence and asked to finish that sentence with an 
incongruent word.  
Trail-making test. The Trail Making Test (Reitan, 1958) involves participants 
quickly connecting circles, and measures speed and executive functioning. In part A of 
the test, participants connected circles with numbers in them in increasing order, which 
measures attention and psychomotor speed. In part B, participants linked circles 
containing both numbers and letters in increasing order, a measure of working memory. 
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Visual analog scales. Three Visual Analogue Scales measuring participant’s 
pain intensity, degree of distress and interference with functioning were used 
Measures used in empirical study. During piloting it was evident that several 
changes needed to be made. This study is a joint project, and time to complete the 
combined measures was too lengthy. In addition, it was discovered that due to their 
levels of pain or disability, measures that required participants to write or interact 
physically with testing stimuli were not feasible. Due to time constraints, the Spot-The-
Word and the Hayling Sentence Completion tasks were removed. The N-Back task, 
which is both time consuming and involves physical interaction with test material, was 
removed, and the Trail Making Task, which involves participant interaction in the form 
of connecting circles with a pencil was removed.  
The removed tasks were measures of response initiation and response inhibition 
(Hayling), attention and working memory (N-Back), psychomotor speed and working 
memory – switching (Trails A & B), and verbal IQ (Spot the Word). The Story Recall 
task, a measure of immediate and delayed episodic memory was retained, and two 
further cognitive measures were added: A Serial Sevens Subtraction task, which 
measures attention and working memory, and a Verbal Fluency task. These tasks use 
verbal instructions, and require verbal responses from participants. They are short, and 
do not require physical interaction with testing materials, and so were more appropriate 
for the study population. 
3.13 Assumptions about Quality of Life with Chronic Pain 
  Pain and especially chronic pain has always been of interest to me. My beloved 
late Grandfather suffered from years of chronic pain as a result of severe arthritis and a 
series of unsuccessful spinal reconstruction surgeries. He was a strong, active and 
independent man, who hated the reduced mobility his pain caused, and who often had 
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periods of low mood due to this. However he cared deeply for his family, and pushed 
through the pain so he could be involved in all aspects of family, work and social life. I 
watched him try treatment after treatment, consulting with pain experts and visiting pain 
management centres in several countries, but getting no real relief, and my heart broke 
for him. 
Personally, during a period of extreme stress five years ago, I experienced a 
week-long episode of trigeminal neuralgia. During this relatively short period of time, I 
was unable to sleep or eat. By the time the neuralgia was diagnosed accurately and 
treated pharmacologically, I was suicidal and experiencing visual and auditory 
hallucinations.  
 Because of my pervious experiences, I expected patients with longstanding 
chronic pain to have a reduced quality of life, to be depressed, and to feel hopeless. 
Indeed, before starting this study, the researchers visited the study site in order to speak 
to patients, meet the medical staff, and to get an idea of the drug administration 
procedure. Patients at that visit spoke of significantly decreased functioning and low 
mood as a result of longstanding chronic pain.  
 However, during the course of the study, interacting with participants forced me 
to re-evaluate my views. While there were participants who reported feeling low and 
frustrated, many participants reported that they had come to terms with their pain and 
the limitations it caused them. Several participants receiving ketamine or lidocaine for 
the first time reported that while they had undergone many unsuccessful 
pharmacological treatments to manage their pain, they continued to be hopeful that this 
new treatment would be beneficial. Other participants were regularly receiving 
lidocaine or ketamine every few months. They reported that while the effects of the 
drugs wore off before they were able to have another dose they felt grateful for the 
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periods during which they experienced decreased pain and increased functioning. 
Though participants were in obvious pain during the pre-drug portion of the study, they 
were willing and eager to help, and reported being happy to work with researchers.  
It is important to note that research has indicated that while there is a 
relationship between global quality of life and chronic pain, this relationship is not 
linear, and is in fact moderated by variables such as stress, fatigue and social support 
(Wahl et al, 2009). Indeed, in line with my experience of pain patients, quality of life is 
more associated with the patient’s beliefs about their pain than it is with the intensity of 
that pain (Lam, Peters, Vlaeyen, Kleef, & Patijn, 2005). 
3.14 Assumptions about the Pain Team 
  My expectations of the pain team at the study site were similar to my 
expectations of pain patients. I made the assumption that due to their work with people 
with irreversible chronic pain, they might feel negative about patient outcomes. In turn, 
I assumed they might feel disillusioned with the work they were doing, and experience 
significant job burnout. I also assumed that they would not be happy to have their 
workspace invaded by researchers and their valuable time spent in helping us. Indeed, 
research on physicians working with chronic pain patients show that persons in this 
field show higher levels of burnout than other physicians (Lapa, Carvalho, Valentim, 
Viana, & Pinto-Gouveia, 2017; Riquelme et al, 2018).  
 Again, working with staff at the study site made me re-evaluate my assumptions. 
The team was welcoming, interested in the research being carried out, and were always 
available to answer questions and give help if needed. Working with such a friendly 
team was a genuine delight, and their attitude towards patients was inspiring. They 
obviously cared about their patients, and did everything they could to make them 
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comfortable including making time for patient questions, empathically listening to 
patients, and explaining procedures clearly and without the use of jargon.  
 There are several factors which moderate burnout, such as beliefs about chronic 
pain, trust in and support from co-workers, levels of professional self-efficacy, low 
organisational cynicism and views of the working environment. (Rodrigues, Cohen, 
Swartout, Trotochaud, & Murray, 2018; Simha, Elloy & Huang, 2014). During the data 
collection period, the researchers saw staff exhibit empathy and support each other 
during difficult periods. The supervising nurse appeared to make every attempt to 
organise shifts to best suit staff, staff made each other cups of tea and brought in treats 
to share, and everyone I interacted with seemed to genuinely enjoy their work. I believe 
that the protective behaviours that the highly professional staff at the study site 
exhibited helped to mediate several of the negative effects of working with chronic pain.    
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Appendix 1.A: Creation of Search Terms 
Table 1. 
Thesaurus Results for Memory in EMBASE, MedLine and PsycINFO 
Search Term EMBASE 
Thesaurus 
MedLine Tree PsycInfo Thesaurus 
Memory Broader terms: 
memory/ or 
brain function/ 
or cognition/ 
Broader 
terms: 
mental 
processes/ or 
memory/ 
 
Related terms: 
memory/ or amnesia/ or chunking/ or cognitive 
processes/ or cued recall/ or cues/ or declarative 
knowledge/ or forgetting/ or free recall/ or 
"generation effect (learning)"/ or hindsight bias/ 
or human information storage/ or information 
processing model/ or "interference (learning)"/ or 
latent inhibition/ or learning/ or matching to 
sample/ or "memory and learning measures"/ or 
memory disorders/ or memory training/ or 
metacognition/ or note taking/ or procedural 
knowledge/ or prompting/ or "recall (learning)"/ 
or relearning/ or retention/ or rote learning/ or 
serial recall/ or source monitoring/ or "tip of the 
tongue phenomenon"/ 
Brain 
Function 
Broader terms: 
brain function/ 
or central 
nervous system 
function/ 
No Tree 
 
Not in thesaurus 
Cognition Broader terms: 
cognition/ or 
mental 
function/ 
Broader 
terms: 
mental 
competency/ 
or mental 
health/ or 
mental 
processes/ 
 
Related terms: 
cognition/ or cognitive development/ or cognitive 
impairment/ or cognitive linguistics/ or cognitive 
processes/ or cognitive science/ or information 
processing model/ or intuition/ or metacognition/ 
or need for cognition/ 
Mental 
Function 
Broader terms: 
mental 
function/ or 
"biological 
phenomena and 
functions 
concerning the 
entire 
organism"/ 
No Tree 
 
Not in thesaurus 
 
Neuropsych-
ological  
OR   
neuropsych 
-ology 
Broader terms: 
Psychology 
Broader 
terms: 
Psycho-
physiology 
Broader Terms 
neurosciences, physiological psychology, 
psychological assessment   
Related Terms 
behavioral neuroscience, neurocognition, 
neuroeconomics, sychoneuroimmunology, social 
neuroscience, bender gestalt test, benton revised 
visual retention test, body sway testing, brain 
damage, cognitive assessment, diagnosis, memory 
for designs test, neuropsychological testing, 
traumatic brain injury  
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Table 2. 
Unsuitable Search Terms Removed 
Included Removed 
"memory and learning measures" 
"recall (learning)"/ or  
amnesia/ or  
brain function/ or  
chunking/ or  
cognition/ or  
cognitive development/ or  
cognitive impairment/ or  
cognitive processes/ or  
cued recall/ or  
declarative knowledge/ or  
forgetting/ or  
free recall/ or 
human information storage/ or 
latent inhibition/ or  
learning/ or  
matching to sample/ or  
memory disorders/ or  
memory training/ or  
memory/ or  
mental competency/ or  
mental function/ or  
mental processes/ or  
metacognition/ or  
neurocognition/ or 
neuropsychological/ or 
neuropsychology/ or  
procedural knowledge/ or  
prompting/ or  
recall/ or 
relearning/ or  
retention/ or  
rote learning/ or  
serial recall/ or  
source monitoring/  
"biological phenomena and functions concerning the entire 
organism"/ 
"generation effect (learning)"/ or 
"interference (learning)"/ or  
"tip of the tongue phenomenon"/ OR  
behavior and behavior mechanisms"/ or  
behavioral neuroscience 
bender gestalt test 
benton revised visual retention test 
body sway testing 
brain damage 
central nervous system function/ or 
cognitive assessment 
cognitive linguistics 
cognitive science/ or  
cues/ or 
diagnosis 
hindsight bias/ / or  
information processing model/ or  
information processing model/ or  
intuition/ or  
memory for designs test 
mental health/ or  
need for cognition/ or  
neuroeconomics 
neuropsychological testing 
neurosciences 
note taking/ or  
physiological psychology 
psychological assessment     
psychophysiology 
psychological phenomena/  
Psychology 
psychoneuroimmunology 
social neuroscience 
traumatic brain injury  
 
Search Terms – Memory 
"memory and learning measures"/ or "recall (learning)"/ or amnesia/ or brain function/ 
or chunking/ or cognition/ or cognitive development/ or cognitive impairment/ or 
cognitive processes/ or cued recall/ or declarative knowledge/ or forgetting/ or free 
recall/ or human information storage/ or latent inhibition/ or learning/ or matching to 
sample/ or memory disorders/ or memory training/ or memory/ or mental competency/ 
or mental function/ or mental processes/ or metacognition/ or neurocognition/ or 
neuropsychological/ or neuropsychology/ or procedural knowledge/ or prompting/ or 
recall/ or relearning/ or retention/ or rote learning/ or serial recall/ or source monitoring/ 
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Appendix 1.B: Search Process 
Table 1 
Search Terms & Limits 
 Terms Results 
1.  "memory and learning measures"/ or "recall (learning)"/ or 
amnesia/ or brain function/ or chunking/ or cognition/ or 
cognitive development/ or cognitive impairment/ or cognitive 
processes/ or cued recall/ or declarative knowledge/ or 
forgetting/ or free recall/ or human information storage/ or latent 
inhibition/ or learning/ or matching to sample/ or memory 
disorders/ or memory training/ or memory/ or mental 
competency/ or mental function/ or mental processes/ or 
metacognition/ or neurocognition/ or neuropsychological/ or 
neuropsychology/ or procedural knowledge/ or prompting/ or 
recall/ or relearning/ or retention/ or rote learning/ or serial 
recall/ or source monitoring/ 
1217324 
 
2.  Cognit* 1458144 
3.  1 OR 2 2012442 
4.  Ketamine 58223 
5.  3 AND 4 4468 
6.  Limit 5 to english language 4260 
7.  Limit 6 to human 2843 
8.  limit 7 to "300  adulthood <age 18 yrs and older>"  
[Limit not valid in Embase,Ovid MEDLINE(R),Ovid 
MEDLINE(R) Daily Update,Ovid MEDLINE(R) In-
Process,Ovid MEDLINE(R) Publisher; records were retained] () 
2720 
9.  limit 8 to adulthood <18+ years>  
[Limit not valid in Embase,Ovid MEDLINE(R),Ovid 
MEDLINE(R) Daily Update,Ovid MEDLINE(R) In-
Process,Ovid MEDLINE(R) Publisher; records were retained]  
2720 
10.  limit 9 to (adult <18 to 64 years> or aged <65+ years>)  
[Limit not valid in PsycINFO,Ovid MEDLINE(R),Ovid 
MEDLINE(R) Daily Update,Ovid MEDLINE(R) In-
Process,Ovid MEDLINE(R) Publisher; records were retained]  
875 
11.  limit 10 to (clinical trial or randomized controlled trial or 
controlled clinical trial) [Limit not valid in PsycINFO; records 
were retained] (299) 
299 
12.  limit 11 to "0300 clinical trial" [Limit not valid in Embase,Ovid 
MEDLINE(R),Ovid MEDLINE(R) Daily Update,Ovid 
MEDLINE(R) In-Process,Ovid MEDLINE(R) Publisher; 
records were retained] (283) 
283 
13.  limit 12 to clinical trial, all [Limit not valid in 
Embase,PsycINFO; records were retained] (283) 
283 
14.  remove duplicates from 13 219 
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Appendix 1.C: Tool Used to Assess Studies 
 
Checklist for Measuring Study Quality 
 
Downs, S. H., & Black, N. (1998). The feasibility of creating a checklist for the 
assessment of the methodological quality both of randomised and non-randomised 
studies of health care interventions. Journal of Epidemiology & Community 
Health, 52(6), 377-384. 
 
Reporting 
 
1. Is the hypothesis/aim/objective of the study clearly described? 
Yes 1 
No 0 
 
2. Are the main outcomes to be measured clearly described in the Introduction or 
Methods section? 
If the main outcomes are first mentioned in the Results section, the question should be 
answered no. 
Yes 1 
No 0 
 
3. Are the characteristics of the patients included in the study clearly described? 
In cohort studies and trials, inclusion and/or exclusion criteria should be given. In case-
control studies, a case-definition and the source for controls should be given. 
Yes 1 
No 0 
 
4. Are the interventions of interest clearly described? 
Treatments and placebo (where relevant) that are to be compared should be clearly 
described. 
Yes 1 
No 0 
 
5. Are the distributions of principal confounders in each group of subjects to be 
compared clearly described? 
A list of principal confounders is provided. 
Yes 2 
Partially 1 
No 0 
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6. Are the main findings of the study clearly described? 
Simple outcome data (including denominators and numerators) should be reported for 
all major findings so that the reader can check the major analyses and conclusions. (This 
question does not cover statistical tests which are considered below). 
Yes 1 
No 0 
 
7. Does the study provide estimates of the random variability in the data for the main 
outcomes? 
In non-normally distributed data the inter-quartile range of results should be reported. In 
normally distributed data the standard error, standard deviation or confidence intervals 
should be reported. If the distribution of the data is not described, it must be assumed 
that the estimates used were appropriate and the question should be answered yes. 
Yes 1 
No 0 
 
8. Have all important adverse events that may be a consequence of the intervention 
been reported? 
This should be answered yes if the study demonstrates that there was a comprehensive 
attempt to measure adverse events. (A list of possible adverse events is provided). 
Yes 1 
No 0 
 
9. Have the characteristics of patients lost to follow-up been described? 
This should be answered yes where there were no losses to follow-up or where losses to 
follow-up were so small that findings would be unaffected by their inclusion. This 
should be answered no where a study does not report the number of patients lost to 
follow-up. 
Yes 1 
No 0 
 
10. Have actual probability values been reported (e.g.0.035 rather than <0.05) for the 
main outcomes except where the probability value is less than 0.001?  
Yes 1 
No 0 
 
External validity 
 
All the following criteria attempt to address the representativeness of the findings of the 
study and whether they may be generalised to the population from which the study 
subjects were derived. 
 
11. Were the subjects asked to participate in the study representative of the entire 
population from which they were recruited?  
The study must identify the source population for patients and describe how the patients 
were selected. Patients would be representative if they comprised the entire source 
population, an unselected sample of consecutive patients, or a random sample. Random 
sampling is only feasible where a list of all members of the relevant population exists. 
Where a study does not report the proportion of the source population from which the 
patients are derived, the question should be answered as unable to determine.  
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Yes 1 
No 0 
Unable to Determine 0 
 
12. Were those subjects who were prepared to participate representative of the entire 
population from which they were recruited?  
The proportion of those asked who agreed should be stated. Validation that the sample 
was representative would include demonstrating that the distribution of the main 
confounding factors was the same in the study sample and the source population.  
Yes 1 
No 0 
Unable to Determine 0 
 
13. Were the staff, places, and facilities where the patients were treated, representative 
of the treatment the majority of patients receive?  
For the question to be answered yes the study should demonstrate that the intervention 
was representative of that in use in the source population. The question should be 
answered no if, for example, the intervention was undertaken in a specialist centre 
unrepresentative of the hospitals most of the source population would attend.  
Yes 1 
No 0 
Unable to Determine 0 
 
Internal validity - bias  
 
14. Was an attempt made to blind study subjects to the intervention they have received?  
For studies where the patients would have no way of knowing which intervention they 
received, this should be answered yes.  
Yes 1 
No 0 
Unable to Determine 0 
 
15. Was an attempt made to blind those measuring the main outcomes of the 
intervention?  
Yes 1 
No 0 
Unable to Determine 0 
 
16. If any of the results of the study were based on “data dredging”, was this made 
clear?  
Any analyses that had not been planned at the outset of the study should be clearly 
indicated. If no retrospective unplanned subgroup analyses were reported, then answer 
yes.  
Yes 1 
No 0 
Unable to Determine 0 
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17. In trials and cohort studies, do the analyses adjust for different lengths of follow-up 
of patients, or in case-control studies, is the time period between the intervention and 
outcome the same for cases and controls?  
Where follow-up was the same for all study patients the answer should yes. If different 
lengths of follow-up were adjusted for by, for example, survival analysis the answer 
should be yes. Studies where differences in follow-up are ignored should be answered 
no.  
Yes 1 
No 0 
Unable to Determine 0 
 
18. Were the statistical tests used to assess the main outcomes appropriate? 
The statistical techniques used must be appropriate to the data. For example 
nonparametric methods should be used for small sample sizes. Where little statistical 
analysis has been undertaken but where there is no evidence of bias, the question should 
be answered yes. If the distribution of the data (normal or not) is not described it must 
be assumed that the estimates used were appropriate and the question should be 
answered yes.  
Yes 1 
No 0 
Unable to Determine 0 
 
19. Was compliance with the intervention/s reliable?  
Where there was noncompliance with the allocated treatment or where there was 
contamination of one group, the question should be answered no. For studies where the 
effect of any misclassification was likely to bias any association to the null, the question 
should be answered yes.  
Yes 1 
No 0 
Unable to Determine 0 
 
20. Were the main outcome measures used accurate (valid and reliable)? 
For studies where the outcome measures are clearly described, the question should be 
answered yes. For studies which refer to other work or that demonstrates the outcome 
measures are accurate, the question should be answered as yes.  
Yes 1 
No 0 
Unable to Determine 0 
 
Internal validity - confounding (selection bias)  
 
21. Were the patients in different intervention groups (trials and cohort studies) or were 
the cases and controls (case-control studies) recruited from the same population?  
For example, patients for all comparison groups should be selected from the same 
hospital. The question should be answered unable to determine for cohort and case 
control studies where there is no information concerning the source of patients included 
in the study.  
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Yes 1 
No 0 
Unable to Determine 0 
 
22. Were study subjects in different intervention groups (trials and cohort studies) or 
were the cases and controls (case-control studies) recruited over the same period of 
time?  
For a study which does not specify the time period over which patients were recruited, 
the question should be answered as unable to determine.  
Yes 1 
No 0 
Unable to Determine 0 
 
23. Were study subjects randomised to intervention groups?  
Studies which state that subjects were randomised should be answered yes except where 
method of randomisation would not ensure random allocation. For example alternate 
allocation would score no because it is predictable.  
Yes 1 
No 0 
Unable to Determine 0 
24. Was the randomised intervention assignment concealed from both patients and 
health care staff until recruitment was complete and irrevocable?  
All non-randomised studies should be answered no. If assignment was concealed from 
patients but not from staff, it should be answered no.  
Yes 1 
No 0 
Unable to Determine 0 
 
25. Was there adequate adjustment for confounding in the analyses from which the 
main findings were drawn?  
This question should be answered no for trials if: the main conclusions of the study 
were based on analyses of treatment rather than intention to treat; the distribution of 
known confounders in the different treatment groups was not described; or the 
distribution of known confounders differed between the treatment groups but was not 
taken into account in the analyses. In nonrandomised studies if the effect of the main 
confounders was not investigated or confounding was demonstrated but no adjustment 
was made in the final analyses the question should be answered as no.  
Yes 1 
No 0 
Unable to Determine 0 
 
26. Were losses of patients to follow-up taken into account?  
If the numbers of patients lost to follow-up are not reported, the question should be 
answered as unable to determine. If the proportion lost to follow-up was too small to 
affect the main findings, the question should be answered yes.  
Yes 1 
No 0 
Unable to Determine 0 
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Appendix 1.D: Detailed Critical Appraisal of Included Studies. 
Table 1. 
Assessment of Reporting 
Study  Hypothesis/ 
aim/objecti
ve clearly 
described 
 
Main 
outcomes 
clearly 
described  
 
Characteristi
cs of the 
patients 
clearly 
described 
 
Intervention
s of interest 
clearly 
described 
 
Distributio
ns of 
principal 
confounder
s clearly 
described? 
(2) 
Main 
findings 
clearly 
described? 
 
Estimates of the 
random 
variability for 
main outcomes 
provided? 
Important 
adverse 
events 
reported 
 
Characteristi
cs of patients 
lost to 
follow-up 
been 
described 
 
Actual 
probabilit
y values 
reported 
 
Tota
l 
(11) 
1996 
LaPorte 
Yes 
Introductio
n 
Yes 
Cognition 
 
Yes 
See: 
Subjects & 
Table 1 
 
Yes 
Ketamine 
(0.5 mg/kg) 
or placebo 
in a bolus 
injection. 
Drug/ 
placebo 
infused over 
1 minute 
Yes 
See: Table 
1 
Yes Yes 
Standard 
deviation 
reported 
No 
No attempt 
to measure 
adverse 
effects 
Yes 
None lost to 
follow up 
Yes 10 
1997 
Malhotra 
Yes 
Introductio
n 
 
Yes 
Cognition 
Behavioura
l effects 
 
Yes 
See: Table 1 
 
Yes 
Placebo OR 
ketamine 
bolus of 
0.12 mg/kg 
then 
infusion of 
0.65 mg/kg 
of ketamine 
(max dose 
58 mg) over 
Yes 
See: Table 
1 
 
Yes Yes 
Standard error 
of mean 
 
Yes 
Via clinical 
observations 
Yes 
None lost to 
follow up 
Yes 11 
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one hour. 
Total dose 
of 0.77 
mg/kg/hr 
 
1997 
Murman 
Yes 
Introductio
n 
Yes  
Cognitive 
function 
Psychiatric 
& physical 
symptoms 
Motor signs 
of HD 
Ketamine 
blood levels 
Yes Yes 
Saline bolus 
+ increasing 
IV ketamine  
0.10, 0.40, 
and 0.60 
mg/kg/hr 
OR Saline 
bolus + IV 
saline x3 
Yes 
Within-
subjects 
Yes 
See Table 1 
& 2 and 
Figure 1 
Yes 
Standard error 
reported 
No 
Adverse 
effects were 
reported, but 
there was no 
comprehensi
ve attempt to 
measure 
them 
Yes 
4 patients 
unable to 
complete 
testing at 
0.6mg/kg/hr 
ketamine 
Yes 10 
2001 
Reeves 
Yes 
Introductio
n 
Yes 
Pain scale 
1-5 
Trail 
making 
PCA opioid 
consumptio
n 
Yes 
See Table 1 
in paper 
Yes.  
PCA 
morphine 1 
mg/mL; 
PCA 
morphine w 
ketamine 1 
mg/mL of 
each  
Yes 
See Table 
1 in paper 
Yes 
See: Table 
2. 
Postoperati
ve 
Outcomes 
Yes 
Standard 
deviations 
provided 
Yes 
Nausea, 
sleep quality, 
vivid 
dreams, 
nausea, 
hallucination
s, pruritus, 
respiratory 
depression, 
Acute Pain 
Service 
interventions 
Yes 
7 lost to 
follow up 
due to: 
inadequate 
analgesia; 
protocol 
violation; 
admitted to 
ICU 
Yes 11 
2002 
Zohar 
Yes 
Introductio
n 
Yes  
Pain. 
Cognitive 
function - 
DSST; 
MMT 
Yes 
See: Table 1 
 
Yes 
PCA device 
with 
0.125% 
bupivacaine 
OR 0.125% 
bupivacaine 
Yes 
See: Table 
1 
 
Yes.  
See: Table 
2 
Yes 
Standard 
deviation/standa
rd error of mean 
reported 
Yes 
BP; heart 
rate & 
respiration; 
follow up: 
fever nausea 
vomiting 
Yes 
None lost to 
follow up 
 
No 
No p or t 
values 
reported 
 
10 
   
126 
 
Adverse 
effects – 
nausea; 
sleepiness; 
anxiety. 
Additional 
morphine 
used. 
and 
ketamine (1 
mg/mL). 
Max 9ml/hr 
of drug  
 
coughing 
dizziness & 
drowsiness 
2008 
Aubrun 
 
Yes 
Introductio
n 
Yes 
Mood 
Cognitive 
function 
Pain 
Yes 
See: Table 1 
Yes 
Patient 
controlled 
analgesia: 
Ketamine 
group: 
combination 
of morphine 
1 mg/ml 
and 
ketamine 
0.5 mg/ml  
Placebo 
group: 
morphine 1 
mg/ml 
alone 
Yes 
See: Table 
1 
Yes 
See: Table 
4 
Yes 
Standard 
deviation 
reported 
Yes 
See: Table 3 
Yes 
12 patients 
excluded: 5 
did not fulfil 
inclusion 
criteria; 
refused to 
participate in 
the study; 
experienced 
major 
surgical 
complication
s 
Yes 11 
2014 
Shiroma 
Yes 
introductio
n 
Yes 
Depression 
symptoms 
Cognitive 
functioning  
Yes 
See: Table 2 
Yes 
All 
participants: 
IV infusion 
of 0.5 
mg/Kg of 
ketamine 
hydrochlori
de  
Yes 
See: Table 
2 
No Yes 
Standard 
deviation 
reported 
No 
Measured 
(Aldrete 
scale) but not 
reported 
Yes 
Described in 
results 
Yes 9 
   
127 
 
6 infusions 
per day over 
2 weeks 
(days: 
1,3,5,8,10,1
2) 
2015 
Murrough 
 
Yes 
Introductio
n  
Yes 
Change in 
depression 
severity 
Cognitive 
functioning  
Yes 
See: Table 1 
Yes 
Ketamine 
group: IV 
infusion of 
ketamine 
(0.5 mg/kg) 
over 40 min 
Active 
control 
group: IV 
infusion of 
midazolam 
(0.045 
mg/kg) over 
40 min 
Yes 
See: Table 
1 
Yes Yes 
Standard 
deviation 
reported 
No 
Not reported 
Yes 
Described in 
results 
Yes  10 
2017 
Grunebau
m 
Yes 
Introductio
n 
Yes 
Suicidal 
ideation 
Depression 
symptoms 
Cognitive 
functioning 
Yes 
See: Table 1 
Yes 
IV racemic 
ketamine 
hydrochlori
de 0.5 
mg/kg OR 
midazolam 
0.02 mg/kg 
in 100 mL 
of normal 
saline over 
40 minutes 
Yes 
See: Table 
1 
No Yes 
Standard 
deviation or 
standard error 
reported 
Yes 
Systematic 
Assessment 
for 
Treatment 
Emergent 
Events; 
Clinician- 
Administere
d 
Dissociative 
States Scale; 
Brief 
Psychiatric 
Yes 
See: Figure 
1 
Yes 10 
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Rating Scale 
(positive 
subscale) 
2018 
Galvez  
Yes 
Introductio
n  
Yes 
Cognitive 
functioning 
Mood 
Quality of 
life 
Side effects 
Ketamine 
& 
norketamin
e plasma 
concentrati
on 
Yes 
See: Table 1 
Yes 
10 sprays of 
100 mg of 
ketamine 3/ 
week for 2 
weeks, then 
weekly for 
2 weeks 
OR 10 
sprays of 
4.5 mg 
midazolam 
3/ week for 
2 weeks, 
then weekly 
for 2 weeks 
Yes 
See: Table 
1 
Yes  Yes 
Standard 
deviations 
reported  
Yes 
See: Table 3 
No 
Characteristi
cs not 
described 
No 
No p 
values 
9 
 
Table 2 
Assessment of External Validity 
Study Subjects invited to participate 
representative of the entire 
population  
Subjects who participated 
representative of the entire 
population  
Staff, places, and facilities 
where the patients were treated 
were representative  
Total (3) 
1996 
LaPorte 
No 
Inpatient research unit 
Unable to determine 
Proportion of whose asked who 
agreed not stated 
No 
Inpatient research unit 
0 
1997 
Malhotra 
Unable to determine 
 
Unable to Determine  
Proportion of those asked who 
agreed not stated 
No 
Specialist Centre 
 
0 
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1997 
Murman 
Unable to Determine  
Proportion of participants to 
source population not reported 
Unable to Determine  
Proportion of those asked who 
agreed not stated 
Yes 1 
2001  
Reeves 
Yes 
All patients presenting for 
elective major abdominal 
surgery involving 
a midline incision were 
identified 
Unable to determine 
Proportion of those asked who 
agreed not stated 
Yes 2 
2002 
Zohar 
Yes 
Randomised 
Unable to determine 
Proportion of those asked who 
agreed not stated 
Yes 2 
2008 
Aubrun 
Unable to determine 
No reporting of proportion of 
source population/ participants 
Unable to determine 
Proportion of those asked who 
agreed not stated 
Yes 1 
2014 
Shiroma 
Unable to determine 
Referred by clinicians in 
primary care & mental health 
Unable to determine 
Proportion of those asked who 
agreed not stated 
No 
Special Diagnostic and 
Treatment Unit 
0 
2015 
Murrough 
Unable to determine Unable to determine 
Proportion of those asked who 
agreed not stated 
No 
Academic medical centre 
0 
2017 
Grunebaum 
Unable to determine 
Recruited via the internet, local 
media and clinician referral 
Unable to determine 
Proportion of those asked who 
agreed not stated 
No 
voluntary admission to an 
inpatient 
research unit at New York State 
Psychiatric Institute 
0 
2018 
Galvez 
Unable to determine 
Source population not identified 
Unable to determine 
Proportion of those asked who 
agreed not stated 
Unable to determine 
Not reported 
0 
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Table 3 
Assessment of Internal Validity - Bias  
Study  Subjects blinded 
to intervention   
Those 
measuring the 
main outcomes 
of the 
intervention 
blind 
Results not 
based on “data 
dredging” 
Analyses 
adjusted for 
differences in 
follow-up/ time 
between 
intervention and 
outcome  
Appropriate 
statistical tests 
used 
 
Reliable  
compliance with 
the 
intervention/s  
 
Main outcome 
measures used 
accurate (valid 
and reliable) 
 
Total (7) 
1996 
LaPorte 
Yes Yes Yes 
No retrospective 
unplanned 
subgroups 
reported 
Yes 
Follow up time 
same for all 
participants 
 
Yes Yes Yes 
Measures clearly 
described 
7 
1997 
Malhotra 
Yes Yes Yes 
No retrospective 
unplanned 
subgroups 
reported 
Yes 
Follow up time 
same for all 
participants 
Yes Yes Yes 
Measures clearly 
described 
7 
1997 
Murman 
Yes Yes Yes 
No retrospective 
unplanned 
subgroups 
reported 
Yes 
Follow up time 
same for all 
participants 
Yes Yes Yes 
Measures clearly 
described 
6 
2001 
Reeves 
Unable to 
Determine 
Unable to 
Determine 
Yes 
No retrospective 
unplanned 
subgroups 
reported 
Yes 
Outcome 
measures 
adjusted for 
length of 
surgery 
Yes Yes Yes 
Measures clearly 
described 
5 
2002 
Zohar 
Yes Yes Yes Unable to 
determine 
Unable to 
determine 
Yes Unable to 
determine 
4 
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No retrospective 
unplanned 
subgroups 
reported 
 p & t values not 
reported 
No description of 
cognitive tests 
used 
 
2008 
Aubrun 
Yes Yes Yes 
No retrospective 
unplanned 
subgroups 
reported 
Yes 
Follow up time 
same for all 
participants 
Unable to 
determine 
p values not 
reported  
Yes Yes 
Measures clearly 
described 
6 
2014 
Shiroma 
No No Yes 
No retrospective 
unplanned 
subgroups 
reported 
Yes 
Follow up time 
same for all 
participants 
Yes Yes Yes 
Measures clearly 
described 
5 
2015 
Murrough 
Yes Yes 
Double blind 
Yes 
No retrospective 
unplanned 
subgroups 
reported 
Yes 
Follow up time 
same for all 
participants 
Yes  Yes Yes 
Measures clearly 
described 
7 
 
2017 
Grunebaum 
Yes  Yes 
Double blind 
Yes 
No retrospective 
unplanned 
subgroups 
reported 
Yes 
Follow up time 
same for all 
participants 
Yes Yes Unable to 
determine 
Neurocognitive 
tasks not escribed 
in detail – what 
are the tests? 
6 
2018 
Galvez 
Yes  Yes 
Double blind 
Yes 
No retrospective 
unplanned 
subgroups 
reported 
Yes 
Follow up time 
same for all 
participants 
Yes  Yes  Yes 
Measures clearly 
described 
7 
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Table 4 
Assessment of Internal Validity - Confounding (Selection Bias)  
Study  Cases and controls 
recruited from the 
same population 
Cases and controls 
recruited over the 
same period of time 
 
Study subjects 
randomised to 
intervention groups 
 
Randomised 
intervention 
assignment 
concealed from 
patients and staff 
Adequate 
adjustment for 
confounding in the 
analyses 
 
Losses of patients 
to follow-up taken 
into account 
 
Total 
(6) 
1996 
LaPorte 
Yes 
Same inpatient 
research unit 
 
Unable to 
determine 
No time period 
given 
 
No 
Alternate allocation 
used 
Yes No 
No adjustment to 
analysis 
Yes 
None lost to follow 
up 
3 
1997 
Malhotra 
Unable to 
determine 
Within-subjects 
but two different 
groups (healthy & 
schizophrenia ) 
Unable to 
determine 
No time period 
given 
Yes 
Within-subjects 
 
Yes Yes 
No confounding 
demonstrated 
 
Yes 
None lost to follow 
up 
4 
1997 
Murman 
Yes 
Within-subjects 
Yes 
Testing 
placebo/ketamine 
separated by a week 
Yes 
Within-subjects, but 
placebo/ketamine 
randomised 
Yes Yes 
Within-subjects 
 
Yes 
Numbers reported 
 
6 
2001 
Reeves 
Yes 
All recruited from 
same hospital 
Unable to 
determine 
No time period 
given 
Yes Unable to 
determine 
Yes Yes 
 
4 
2002 
Zohar 
Yes 
All recruited from 
same hospital 
Unable to 
determine 
No time period 
given 
Yes 
Computer 
generated 
randomisation 
 
Yes 
 
Unable to 
determine 
Statistics not 
reported 
Yes 
None lost to follow 
up 
4 
2008 Yes Yes  Yes Yes Yes Yes 6 
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Aubrun 
 
All recruited from 
same hospital 
The study was 
conducted between 
May 2003 and 
October 2004 
Random number 
table  
 Intent-to-treat 
analysis 
None lost to follow 
up 
2014 
Shiroma 
 
Yes 
Within-subjects 
Unable to 
determine 
No time period 
given 
No 
Within-subjects 
No Unable to 
determine 
Yes 
Reported  
2 
2015 
Murrough 
Unable to 
determine 
Unable to 
determine 
No time period 
given 
Unable to 
determine 
Randomisation 
method not reported 
Yes 
 
Yes 
No adjustment – 
confounders 
appeared balanced 
Yes 
Reported 
3 
2017 
Grunebaum 
Unable to 
determine 
Participants were 
recruited via the 
internet, local 
media and 
clinician 
referral 
Yes 
Enrolment was 
from October 2013 
to August 2015 
with follow-up 
complete in 
December 2015 
Yes 
Permuted block 
randomisation  
Yes  Yes 
No adjustment – 
confounders 
appeared balanced 
Yes 
No loss after 
randomisation  
5 
2018 
Galvez 
Unable to 
determine 
No information 
concerning source 
of participants 
Unable to 
determine 
No time period 
given 
Yes 
Permuted block 
design 
Yes No  
Results based on 
analysis of 
treatment not 
intent to treat 
Yes 
Reported  
3 
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Appendix 2.D: Scoring Guidelines for Story Recall Task 
Table 2.D.1. 
Scoring Guidelines for Story 1 
 Exact Phrase Alternate Score (1) 
1.  Three hundred men Three hundred people 
Three hundred workers 
X-hundred men 
Three hundred employees 
Lots of people 
1.0 
0.5 
0.5 
0.5 
0.0 
2.  walked out Went out 
Left  
0.5 
0.5 
3.  of a car factory A car plant 1.0 
4.  on Clydeside Clydesdale 0.5 
5.  this morning This a.m. 
Today  
1.0 
0.5 
6.  following an announcement   
7.  of large scale redundancies. Because of redundancies 
Job losses 
Lost their jobs 
Laid off 
Going to be sacked 
0.5 
0.5 
0.5 
0.5 
0.5 
8.  Mr David Davies 0.0 
9.  Mitchell   
10.  a company director, Director of the company 
A/the managing director  
A/the director 
A spokesman 
1.0 
0.5 
0.5 
0.0 
11.  told reporters Talked to reporters 
Spoke to the press 
0.5 
0.5 
12.  that the factory   
13.  had suffered losses Losses due to 
Had been recording losses 
0.5 
0.5 
14.  because of high interest rates, Interest rates were higher 
Due to high interest rates 
Because of high interest 
Because of the interest rates 
1.0 
1.0 
1.0 
0.5 
15.  low productivity Productivity  0.5 
16.  and foreign competition. Competition from abroad 
Competition overseas 
1.0 
1.0 
17.  Union officials The unions 
Union people 
Union representatives  
A union 
1.0 
1.0 
1.0 
0.5 
18.  have agreed to begin    
19.  Negotiations In talks with 
To talk 
0.5 
0.5 
20.  with management   
21.  tomorrow   
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Table 2.D.2 
Scoring Guidelines for Story 2 
 Exact Phrase Alternate Score (1) 
1.  A wide stretch A long stretch 
A large stretch 
A stretch of 
A large part of 
A section of 
0.5 
0.5 
0.5 
0.5 
0.5 
2.  of the River Trent A river 0.5 
3.  in Nottinghamshire In Nottingham 0.5 
4.  was closed Was cordoned off 
Was sealed off 
Was shut/ shut it 
Shut down 
Was evacuated 
1.0 
1.0 
1.0 
0.5 
0.5 
5.  by police   
6.  at the weekend This weekend 
Over the weekend 
1.0 
1.0 
7.  when divers   
8.  Discovered Found 1.0 
9.  an old bomb   
10.  from an R.A.F. Lancaster   
11.  which had crashed That had dropped 0.5 
12.  in 1943.   
13.  All the surrounding farms The nearby farms  
All other areas 
The surrounding area 
1.0 
0.5 
0.5 
14.  and villages   
15.  were evacuated Sealed off 
Had to be moved away 
Was closed 
0.0 
1.0 
0.5 
16.  whilst military experts The army 
Bomb disposal unit 
RAF bomb squad 
Bomb experts  
Whilst they 
 
0.5 
0.5 
0.5 
0.5 
0.0 
17.  Detonated Exploded 1.0 
18.  the bomb   
19.  The blast The detonation 
The explosion 
The bomb 
1.0 
1.0 
0.5 
20.  could be heard   
21.  over five miles away Five miles away 0.5 
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Appendix 2.E: Shapiro-Wilk Tests of Normality for Baseline and Midpoint Pain 
and Cognition Scores 
Table 2.E.1 
Shapiro-Wilk Tests of Normality for Baseline and Midpoint Pain and Cognition Scores 
Pain/Cognitive Domain Drug 
Administered 
Shapiro-Wilk 
  Statistic Df Sig. 
Baseline pain intensity Lidocaine .873 34 .001* 
 Ketamine .748 24 .000* 
Baseline pain distress Lidocaine .920 34 .016* 
 Ketamine .902 24 .024* 
Baseline pain interference Lidocaine .845 33 .000* 
 Ketamine .832 24 .001* 
Midpoint pain intensity Lidocaine .947 33 .107 
 Ketamine .933 24 .115 
Midpoint pain distress Lidocaine .928 33 .030* 
 Ketamine .838 24 .001* 
Midpoint pain interference Lidocaine .888 33 .003* 
 Ketamine .807 23 .000* 
Baseline story 1 immediate recall Lidocaine .888 34 .002* 
 Ketamine .897 24 .018* 
Baseline fluency correct Lidocaine .948 34 .108 
 Ketamine .922 24 .063 
Baseline fluency errors Lidocaine .378 34 .000* 
 Ketamine .617 24 .000* 
Baseline fluency repetitions Lidocaine .669 34 .000* 
 Ketamine .733 24 .000* 
Baseline serial sevens Lidocaine .848 34 .000* 
 Ketamine .909 24 .034* 
Midpoint story 2 immediate recall Lidocaine .958 33 .231 
 Ketamine .920 24 .059 
Midpoint fluency correct Lidocaine .973 33 .576 
 Ketamine .972 24 .704 
Midpoint fluency errors Lidocaine .328 33 .000* 
 Ketamine .598 24 .000* 
Midpoint fluency repetitions Lidocaine .641 33 .000* 
 Ketamine .558 24 .000* 
Midpoint serial sevens Lidocaine .934 33 .047* 
 Ketamine .903 24 .025* 
Midpoint story 1 delayed recall Lidocaine .918 33 .016* 
 Ketamine .839 23 .002* 
Midpoint story 2 delayed recall Lidocaine .967 33 .394 
 Ketamine .813 23 .001* 
*. Indicates significance at the 0.05 level  
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Appendix 2.F: Shapiro-Wilk Tests of Normality for Pain and Cognition Change 
Scores 
Table 2.F.1 
Shapiro-Wilk tests of normality for pain and cognition change scores 
Pain/Cognitive Domain Drug 
Administered 
Shapiro-Wilk 
  Statistic Df Sig. 
Pain Intensity Lidocaine 0.951 33 0.147 
 Ketamine 0.953 24 0.317 
Pain Distress Lidocaine 0.959 33 0.243 
 Ketamine 0.984 24 0.961 
Pain Interference Lidocaine 0.876 32 0.002* 
 Ketamine 0.889 23 0.015* 
Verbal Fluency Correct Lidocaine 0.976 33 0.671 
 Ketamine 0.940 24 0.162* 
Verbal Fluency Total Errors Lidocaine 0.837 33 0.000* 
 Ketamine 0.965 24 0.537 
Serial Sevens Lidocaine 0.933 33 0.044 
 Ketamine 0.761 24 0.000* 
Story 1 Recall Lidocaine 0.967 33 0.410 
 Ketamine 0.935 23 0.143 
Story 2 Recall Lidocaine 0.948 33 0.114 
 Ketamine 0.964 23 0.546 
Story Immediate Recall Lidocaine 0.983 33 0.867 
 Ketamine 0.873 24 0.006* 
Story Delayed Recall Lidocaine 0.979 33 0.744 
 Ketamine 0.940 23 0.177 
*. Indicates significance at the 0.05 level 
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Appendix 2.G: Statement of Joint Working 
 
This was a joint project carried out by two UCL Doctorate in Clinical 
Psychology trainees. The partner project evaluates the effect of ketamine on mood.  
Proposals for each project were completed independently, with the exception of 
the methods section which was a joint collaboration.  
Collection of data was completed by the two trainees, with help from UCL 
Researcher Dr Will Lawn. 
Statistical analysis and write up of this empirical paper was completed by myself 
alone, as was Part 1, the Literature Review.   
 
